

# CURRICULUM VITAE

**Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

## **BUSINESS ADDRESS**

College of Pharmacy  
University of Michigan  
428 Church Street  
Ann Arbor, MI 48109-1065  
Telephone: 734-764-7144  
Fax: 734-763-2022  
ORCID: 0000-0002-1808-7904  
E-mail: [muellerb@med.umich.edu](mailto:muellerb@med.umich.edu)

## **PHARMACY LICENSURE**

Wisconsin #10674  
Michigan # 5302033238

## **EDUCATION**

1985 - 1988                      Doctor of Pharmacy  
   College of Pharmacy  
   The University of Texas at Austin and  
   The University of Texas Health Science Center at San Antonio

1981 - 1984                      Bachelor of Science in Pharmacy  
   School of Pharmacy  
   University of Wisconsin, Madison, Wisconsin

1979 - 1981                      Pre-pharmacy  
   University of Wisconsin – Milwaukee, Milwaukee, Wisconsin  
   University of Wisconsin – Parkside, Kenosha, Wisconsin

## **POSTGRADUATE TRAINING**

July 1987 - June 1988            Adult Internal Medicine Residency  
   The University of Texas at Austin and  
   The University of Texas Health Science Center at San Antonio  
   Preceptor - Robert L. Talbert, Pharm.D.

## **EMPLOYMENT**

July 2022-Present                Professor  
   Clinical Pharmacy Department, College of Pharmacy

July 2020 – June 2022            Interim Dean

February 2020 – June 2020      Professor and Senior Associate Dean  
   Clinical Pharmacy Department, College of Pharmacy

September 2011 – January 2020   Professor and Associate Dean for Academic Affairs  
   Clinical Pharmacy Department, College of Pharmacy

July 2000-September 2011      Professor and Department Chair  
   Clinical, Social, and Administrative Sciences, College of Pharmacy  
   and  
   Assistant Director  
   Department of Pharmacy Services, University Hospital  
   University of Michigan, Ann Arbor, Michigan

## **Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

July 1999 - June 2000	Professor of Pharmacy Practice Purdue University, School of Pharmacy Indiana University Medical Center, Indianapolis, Indiana
September 1990 - June 2000	Adjunct Assistant Professor of Medicine Indiana University, Indianapolis, Indiana
July 1993 - July 1999	Associate Professor of Clinical Pharmacy Purdue University, School of Pharmacy
July 1988 - June 1993	Assistant Professor of Clinical Pharmacy Purdue University, School of Pharmacy
July 1985 - June 1988	Staff Pharmacist Medical Center Hospital, San Antonio, Texas
July 1984 - July 1985	Pharmacy Intern St. Luke's Memorial Hospital, Racine, Texas

### **AWARDS AND CERTIFICATIONS**

2020	University of Michigan Center for Interprofessional Education Distinguished Leadership Award
2017	St. Catherines's High School (Racine, WI) Alumni Hall of Fame Inductee
2015	American College of Clinical Pharmacy's Critical Care PRN Research Award
2015	Michigan Institute for Clinical & Health Research Distinguished Clinical and Translational Research Mentor Award
2015	Visiting Professor at Baxter Healthcare
2015	65th Annual University of Wisconsin Kremers Lecturer, Madison, Wisconsin
2015	University of Michigan Provost's Teaching Innovation Prize (Faculty Team Lead: Burgunda Sweet)
2013	University of Michigan Road Scholar
2011	University of Michigan College of Pharmacy Teaching Excellence Award
2010	Fellow of the National Kidney Foundation
2009	Fellow of the American Society of Nephrology
2007-2008	Pharmacy Student Appreciation Award, Selected by University of Michigan P-2 Students. University of Michigan College of Pharmacy
2007	Nominated for Teaching Excellence Award, University of Michigan College of Pharmacy
1991 - 2004	Board Certified Pharmacotherapy Specialist, BCPS# 291281
2003 - 2004	Pharmacy Student Appreciation Award, selected by U Michigan P-3 students
1999 - 2000	University Faculty Scholar, Purdue University

## **Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

1999	Outstanding Clerkship Instructor, selected by Purdue Doctor of Pharmacy Class of 1998-99
1998	Tony and Mary Hulman Excellence in Health Science Research Award, Public Health Foundation Indiana
1997	1997 Heine Award for Best Faculty Educator, Purdue University School of Pharmacy and Pharmacal Sciences
1997 - 1998	Who's Who in Medicine and Healthcare
1996	Fellow, American College of Clinical Pharmacy
1995	Clerkship Instructor of the Year, selected by Purdue Doctor of Pharmacy Class of 1994-95
1985 - 1988	The University of Texas Graduate School Competitive Scholarship - The University of Texas
1987	Radiation Safety Certification
1987	Rho Chi National Honor Society
1984	Wisconsin Pharmaceutical Association Outstanding Member of Graduating Class
Fall 1983 - Spring 1984	University of Wisconsin Honor Roll
1982 - 1984	Kappa Psi Scholarship Award

### **ACTIVITIES AND OFFICES**

2019-Present	Senior editor, Lexicomp, Wolters Kluwer, Health.
2000-2018	Member, International CRRT Conference Organization Committee
2016	Abstract Category Chair for Pharmacokinetics (PK)/Pharmacodynamics (PD)/Pharmacogenomics, American Society of Nephrology
2015	ASHP Student Poster Reviewer
2014	ACCP Annual Meeting Abstract Reviewer
2014	University of Toledo PharmD Summit Facilitator
2013-4	Member, ASHP Vancomycin Usage and Monitoring Guideline Task Force
2013	Student Poster Mentor, ASHP Midyear Meeting
2012-3	Member, American Society of Nephrology 2013 Program Committee
2008	Food & Drug Administration, Center for Drug Evaluation Research, Advisory Committee for Pharmaceutical Science and Clinical Pharmacology (ACPS-CP) March 18-19, 2008, Rockville Maryland.
2006-2008	Member, Michigan Pharmacists Association Education Committee

## **Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

2004-2005	Chairman, ACCP Awards Committee
2004	Meeting Programming Associate (MPA), ASHP Midyear Clinical Meeting, December 5-9, 2004, Orlando, Florida
2004	Member, Junior Investigator in Critical Care Research Grant Program Review, ASHP Research and Education Foundation
August 2004	Visiting Professor, Food and Drug Administration, August 9-10, 2004, Bethesda, Maryland
2003-2004	Chairman, ACCP Awards Committee
September 2002	Member, 2003 ACCP Awards Committee/Task Force
2001	Advisory Board, Amgen, Inc.
2001-2010	Editorial Board, Pharmacotherapy
1993-2003	Chair, Editorial Board, Pharmacotherapy Self-Assessment Program, 4th edition
1995-Present	Nephrology Editorial Panel, Annals of Pharmacotherapy
1996-1999	Editorial Board, Pharmacotherapy Self-Assessment Program, 3rd edition
1996-1999	Secretary, American College of Clinical Pharmacy
1999	Pharmacy Practice Department Review Committee for Purdue Research Foundation Research Grant Submissions
1999	Pharmacist Counselor for the Alliance of Pharmaceutical Care at the National Conference of State Legislatures, July 24, 1999, Indianapolis, Indiana
1997	Adult Medicine Specialty Practice Residency Site Accreditation Survey Team, American Society of Hospital Pharmacists
1996-1997	Member, American College of Clinical Pharmacy Publications Committee
1990-1996	Editorial Staff, Pharm Facts: Bulletin of the Pharmacy and Drug Information Center of Indiana University Hospitals, Indianapolis, Indiana
1996	Great Lakes Pharmacy Resident Conference Planning Committee
1990-1994	ACCP Regional Recruiter
1990-1996	Primary Preceptor, Adult Medicine Pharmacy Practice Specialty Residency, Purdue University Department of Pharmacy Practice
1995	Chair, 1996 American College of Clinical Pharmacy Winter Practice and Research Forum Planning Committee
1991-1994	Adult Medicine Specialty Practice Residency Site Accreditation Survey Team, American Society of Hospital Pharmacists
1993-1994	Chair, 1994 Winter Practice and Research Forum Program Committee, American College of Clinical Pharmacy
1993	Chair, American College of Clinical Pharmacy Educational Affairs Committee

## **Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

1991 and 1992	Chair, Membership Committee, American College of Clinical Pharmacy
1990-1991	Vice Chair, Membership Committee, American College of Clinical Pharmacy
1990	Co-Chair, Great Lakes Pharmacy Resident Conference, Indianapolis, Indiana
1989-1990	Member, Membership Committee, American College of Clinical Pharmacy
1989	Program Coordinator, Seminars in Clinical Pharmacy Poster Session, Lilly Corporate Center, Indianapolis, Indiana
1987-1988	Chief Resident, Clinical Pharmacy Programs, The University of Texas Health Science Center at San Antonio
1983-1984	Pharmacy Class Vice President, University of Wisconsin
1983-1984	Pharmacy School Student Senate, University of Wisconsin
1983-1984	Kappa Psi Social Chair, University of Wisconsin

### **PROFESSIONAL AFFILIATIONS**

American College of Clinical Pharmacy  
American Association of Colleges of Pharmacy  
American Society of Health-System Pharmacists  
National Kidney Foundation  
American Society of Nephrology  
Michigan Pharmacists Association

### **PATENTS**

Vibration-Assisted Dialysis Method and Apparatus. The Regents of the University of Michigan. Mueller US Serial US 2013/0112620 A1. Publication Date May 9, 2013. UM Ref. No. 4492.

### **GRANTS AND CONTRACTS (FUNDED AND PENDING)**

Imipenem/Relebactam Clearance During Continuous Renal Replacement Therapy (CRRT): An In Vitro Investigation.” Jang SM, **Mueller BA**. Merck. \$99,868 (funded January 2018).

“Update on Time-Motion Activities for Commercially-Available CRRT Solution Preparation”. Jang SM, Clark JS, **Mueller BA**. Baxter, \$31,345 (funded December 2017).

“CD101 Clearance During Continuous Renal Replacement Therapy and Intermittent Hemodialysis: An Ex vivo Investigation”. Jang SM, Shaw A, **Mueller BA** (PI). Cidara Therapeutics. \$107,117 (funded May 2017)

“MB-102 Ex Vivo Study”. **Mueller BA** (PI), Jang SM. MediBeacon, Inc. \$98,517 (funded July 2017).

“Tesaro Study”. **Mueller BA** (PI), Clark, J. CommGeniX, LLC (funded, February 2017-July 2017).

“Phosphate Review Article”. Heung, M., **Mueller BA**. Baxter Healthcare Corporation (funded, September 2016-

## **Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

September 2017).

“Assembling Dialysate Circuit Using Different Components”. **Mueller, BA** (PI). Hope Pharmaceuticals (funded, February 2016-December 2018).

“Time Motion Study of CRRT Solution Preparation”. **Mueller BA** (PI), Shaw A, Chaijamorn W, Clark J. Baxter. \$92,574 (funded December 2015).

“Role of Phosphate Replacement in Patients Receiving CRRT”. **Mueller BA** (PI), Heung M. \$22883 (submitted to Baxter, September 2015)

“Regadenoson Clearance During Hemodialysis: An In vitro Investigation”. **Mueller BA** (PI), Gharibian KN, Lewis SJ. Astellas. \$100,838 (funded, 2015)

“Ceftolozane/Tazobactam Clearance During Continuous Renal Replacement Therapy (CRRT): An In-vitro Investigation”. **Mueller BA** (PI), Lewis SJ, Gharibian KN. Merck. \$97,176.60 (funded, September 2015)

“Dosing of Nucleos(t)ide Reverse Transcriptase Inhibitors during Continuous Renal Replacement Therapy”. Society of Infectious Disease Pharmacists. \$10,500 (not funded).

“Pharmacogenetics of ACE inhibitor activation”. Haojie Zhu (PI), **Mueller BA** (co-investigator). Michigan George M. O'Brien Kidney Translational Core Center (MKTCC) an NIH funded P30 Center. \$40,000 (not funded 2015)

“Interprofessional Health Education and Collaborative Care: A Transformative Model for the Health Sciences”. **Bruce Mueller**, Carol Anne Murdoch-Kinch, Jane Banaszak-Holl, Melissa Gross, Bonnie Hagerty, Edith Kieffer, Rajesh Mangrulkar.(Co-PI's) University of Michigan Transforming Learning for a Third Century (TLTC) Transformation grant program. \$3,000,000. Funding Period January 2015-June 2020. (Funded, November 2014)

“Development of Antibiotic Dosing Regimens for SHIFT Dialysis Therapy”. **Mueller BA** (PI), Lewis SJ. November 2014-October 2015. \$80,000. (Funded, November 2014)

“Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients with Chronic Kidney Disease Stage 5”. PI: **Mueller BA**. Theravance Pharmaceuticals. \$231,641 (Funded) November 2014

“Influence of hemodialysis on intradialytic dosing of telavancin”. PI: **Mueller BA**. Theravance Pharmaceuticals. \$413,000 (funded) November 2014

“Tedizolid Clearance During Continuous Renal Replacement Therapy (CRRT): An In-vitro Investigation”. PI: **Mueller BA**. Cubist Pharmaceuticals. \$59,860 (submitted February 5, 2014) (Funded, January 2015-April 2015).

“Characterization of uremic toxin clearance with vibration assisted hemodialysis”. PI **Bruce A. Mueller**. Co-Investigators: J Bull, M Heung. Sponsor: National Institutes of Health. Pilot and Feasibility Clinical Research Grants in Diabetes, and Endocrine and Metabolic Diseases (NIH R21). \$427,625 (\$275,000 Direct costs) [not funded]

“Determination of Telavancin Dosing in Patients Receiving Maintenance Hemodialysis via Analysis of Pharmacokinetics and Hemodialysis Clearance”. PI: Bruce A Mueller. Sponsor: Theravance, Inc. November, 2012. \$183,480. [not funded]

“The Pharmacokinetics and Pharmacodynamics of Daptomycin 2-minute IV injection in Patients with Chronic Kidney Disease Receiving Hemodialysis”. PI: **Bruce A. Mueller**. Sponsor: Cubist Pharmaceuticals, Inc. December, 2011, \$230,000. [not funded]

“Effects of vibration of clearance during hemodialysis performed with a standard permeability dialyzer.” PI: **Bruce A. Mueller**. Sponsor: Michigan Institute for Clinical & Health Research. February 7, 2013; \$49,745.

## **Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

“Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients.” PI: **Bruce A. Mueller**. Sponsor: Gilead Sciences, Inc. January 1, 2011, \$120,000.

“Pharmacokinetics of Oseltamivir in Critically Ill Patients.” PI: **Bruce A. Mueller**. Sponsor: Roche. November 2009; \$246,726.

“Pharmacokinetics of Invanz® in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis.” PI: **Bruce A. Mueller**. Sponsor: Merck. May 2008; \$106,856.

“Dalbavancin Clearance During Intermittent and Continuous Renal Replacement Therapy (CRRT): An In-vitro Investigation.” PI: **Bruce A. Mueller**. Sponsor: Pfizer Inc. May 12, 2008; \$99,369.

“Pharmacokinetics of Cubicin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD).” PI: **Bruce A. Mueller**. Sponsor: Cubist Pharmaceuticals. November 2006; \$96,654.

“Pharmacokinetic Evaluation of Intradialytic Administration of Daptomycin and the Pharmacodynamic Effects of Intradialytic Administration and MRSA.” PI: **Bruce A. Mueller**. Sponsor: Cubist Pharmaceuticals; \$77,119 (pending). May 2006.

“Pharmacotherapy in Renal Disease. CE Program Support.” PI: **Bruce A. Mueller**. Sponsor: Gambro; \$5000.

“Pharmacotherapy in Renal Disease. CE Program Support.” PI: **Bruce A. Mueller**. Sponsor: Genzyme; \$5000.

“Pharmacotherapy in Renal Disease. CE Program Support.” PI: **Bruce A. Mueller**. Sponsor: Amgen; \$5000.

“Pharmacotherapy in Renal Disease. CE Program Support.” PI: **Bruce A. Mueller**. Sponsor: Cubist Pharmaceuticals; \$5000.

“Invanz™ Clearance in Continuous Renal Replacement Therapy (CRRT): An In-vitro Investigation.” PI: **Bruce A. Mueller**. Sponsor: Merck. April 2006; \$52,399.

Nephrology Mini-Sabbatical. Mentor: **Bruce A. Mueller**. Sponsor: American College of Clinical Pharmacy. Total award \$3,500; \$750 University of Michigan.

“Pharmacokinetics of Telavancin During Continuous Renal Replacement Therapy (CRRT): An In-Vitro Investigation.” PI: **Bruce A. Mueller**. Sponsor: Theravance, Inc. May 2005; \$55,509.

“Intradialytic Daptomycin Administration and Protein Binding in Chronic Hemodialysis Patients.” PI: **Bruce A. Mueller**. Sponsor: Cubist Pharmaceuticals. May 2005; \$96,129.

“Transplacental Passage of Vancomycin Following Single Dose Administration to Cesarean Section.” PI: Kristin C. Klein, Co-investigator: **Bruce A. Mueller**. Sponsor: American Foundation for Pharmaceutical Education. December, 2004; \$7,930.

“Accelerating Anti-Seizure Medication Removal During Continuous Hemodialysis (CVVHD) with an Albumin-based Dialysate.” National Kidney Foundation of Michigan. November, 2004; \$30,959.

“Protein Bound Drug Removal during Continuous Renal Replacement Therapy (CRRT) with an Albumin-based Dialysate: An In-vitro Investigation.” PI: **Bruce A. Mueller**, Co-investigator: Mariann D. Churchwell, Deborah A. Pasko, and Smoyer W. Sponsored: Mott Foundation Grant; 2004-2005; \$27,500.

“Pharmacokinetics of Cidecin® During Continuous Renal Replacement Therapy.” PI: **Bruce A. Mueller**, Co-Investigator: Deborah A. Pasko. Sponsor: Cubist Pharmaceuticals, \$25,715.

“Promoting Responsible Interaction Between Industry and VA Health Systems.” PI: **Bruce A. Mueller**. Sponsor: Novartis Pharmaceuticals Inc. November 19-21, 2002; \$43,750.

## **Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

“Promoting Responsible Interaction Between Industry and VA Health Systems.” PI: **Bruce A. Mueller**. Sponsor: Novartis Pharmaceuticals Inc. October 28-30, 2002; \$43,750.

“Promoting Responsible Interaction Between Industry and VA Health Systems.” PI: **Bruce A. Mueller**. Sponsor: Novartis Pharmaceuticals Inc. October 8-10, 2002; \$35,000.

“Longitudinal Hemodiafilter Performance with Three Continuous Renal Replacement Therapy (CRRT) Modes.” Sponsor: National Kidney Foundation. August 20, 2002; \$25,000.

“Promoting Responsible Interaction Between Industry and VA Health Systems.” PI: **Bruce A. Mueller**. Sponsor: Novartis Pharmaceuticals Inc. August 6-8, 2002; \$42,000.

2002 ACCP-Bayer Critical Care Research Fellowship, Deborah Pasko, Fellow. American College of Clinical Pharmacy. July 1, 2002, \$22,500.

“Promoting Responsible Interaction Between Industry and VA Health Systems.” PI: **Bruce A. Mueller**. Sponsor: Novartis Pharmaceuticals Inc. March 18-20, 2002; \$43,750.

“Promoting Responsible Interaction Between Industry and Health Systems”. PI: **Bruce A. Mueller**. Sponsor: Novartis Pharmaceuticals Inc. January 29-31, 2002; \$54,000.

“In vitro hemofiltration research support.” PI: **Bruce A. Mueller**, Co-Investigator Deborah Pasko. Materiel support of a Diapact<sup>®</sup> Hemofiltration machine. January 2002, value \$25,000.

“Shared Instrument Support for Clinical Research in the College of Pharmacy.” PI: **Bruce A. Mueller**. Sponsor: Office of the Vice President for Research Faculty Grants and Awards. November, 2001; \$36,666.

“Shared Instrument Support for Clinical Research in the College of Pharmacy.” PI: **Bruce A. Mueller**. Sponsor: College of Pharmacy Shared Equipment Grant Faculty Grants and Awards. November, 2001; \$23,000.

“Longitudinal Hemodiafilter Performance in Diffusive and Convective Modes.” PI: **Bruce A. Mueller**. Co-investigator: Deborah A. Pasko. Sponsor: Clinical Research Resources Committee, Department of Clinical Sciences, College of Pharmacy. October, 2001; \$24,983.

“Gender Differences in the Relationship Between Levofloxacin Vss and Body Weight.” Principal Investigator and Fellowship Preceptor: Kevin M. Sowinski. Co-investigators: **Bruce A. Mueller** and Michael B. Kays. Fellow: Cindy K. Clemmons. Sponsor: American College of Clinical Pharmacy Research Institute, Aventis Pharmaceuticals Research Fellowship. July 2000 – June 2002; \$45,000.

“Solute Removal Characteristics of a CAHP210 Dialyzer: Using an In Vitro Model to Predict In Vivo Performance.” Principal Investigator: Meri K. Scott. Co investigators: Kevin M. Sowinski, **Bruce A. Mueller**. Sponsor: National Kidney Foundation of Indiana, Inc. February 2000; \$8,137.

“Pharmacokinetics of intravenous cefazolin in hemodialysis patients.” PI: **Bruce A. Mueller** (Co-PI); Marx MA (Co-PI); Bailie GR (Co-PI); Grabe DW (Co-investigator); Manley HJ (Co-investigator) National Kidney Foundation of Northeast New York Inc. Roger E. Coene Research Award. Funded for \$7,000.

“University Faculty Scholar.” Recipient: **Bruce A. Mueller**. Sponsor: Purdue University. 1999 – 2003; \$50,000.

“Fluoroquinolone Bioavailability When Co Administered with RenaGel.” Co PI: **Bruce A. Mueller**, Kevin M. Sowinski, Michael B. Kays. Sponsor: Geltex Pharmaceuticals. 1999; \$45,500.

Educational Grant. Co-PI: Michael B. Kays, **Bruce A. Mueller** and Kevin M. Sowinski. Sponsor: Pfizer Pharmaceuticals. June 1999; \$22,000.

“Characterization of LY (LY203638) Removal During Hemodialysis and Hemofiltration.” PI: Meri K. Scott. Co-investigator: **Bruce A. Mueller**. Sponsor: Eli Lilly and Company. May 1998; \$123,266.

“Gender Differences in Beta-2 Adrenoceptor Responsiveness in ESRD.” PI: Kevin M. Sowinski. Co-investigators: Meri K. Scott and **Bruce A. Mueller**. Sponsor: American College of Clinical Pharmacy. May 1998; \$10,000.



## **Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

“Effect of PAHP Dialyzer Reuse on Drug and Solute Removal.” PI: Kevin M. Sowinski. Co-investigators: Meri K. Scott and **Bruce A. Mueller**. Sponsor: American College of Clinical Pharmacy. 1997; \$9,999.

“Intradialytic Nepro® Effects on the Quality of Life of Patients Receiving Hemodialysis.” Co-PI: Meri K. Scott and **Bruce A. Mueller**. Sponsor: Ross Laboratories, Materiel Support. March 1998; \$6,480.

“Pharmacokinetic-Pharmacodynamic Modeling of Terbutaline-Induced Hypokalemia in Patients with End-Stage Renal Disease.” PI: Kevin M. Sowinski. Co-Investigator: **Bruce A. Mueller**. Sponsor: National Kidney Foundation of Indiana, Inc. 1998; \$10,000.

“Intradialytic Enteral Nutrition Effects on the Quality of Life of Patients Receiving Hemodialysis.” Co-PI: Meri K. Scott and **Bruce A. Mueller**. 1997 Kinley Trust Award; \$10,980.

“Amgen Nephrology Pharmacy Support.” PI: **Bruce A. Mueller**. Sponsor: Amgen Pharmaceuticals. 1997; \$5,000.

“A Comparison of Vancomycin Serum Concentrations Using Fluorescence Polarization Immunoassay (FPIA) and Enzyme Multiplied Immunoassay Technique (EMIT) Assay Methods in Patients Undergoing High-Flux Hemodialysis: Potential Cross-reactivity with Crystalline Degradation Product.” PI: **Bruce A. Mueller**. Co-Investigators: Joanna Rule and Michael A. Kraus. Sponsor: National Kidney Foundation of Indiana, Inc. 1997; \$7,400.

“The Effect of Bleach/Formaldehyde Hemodialyzer Reuse on the Removal of Varying Molecular Weight Solutes During High-Permeability Hemodialysis.” PI: Meri K. Scott. Co-Investigator: **Bruce A. Mueller**. Sponsor: National Kidney Foundation of Indiana, Inc. 1997; \$9,984.

“Effect of Dialyzer Reprocessing on Solute Removal.” PI: **Bruce A. Mueller**. Co-Investigator: Meri K. Scott. Sponsor: Baxter Health Care. 1996; \$45,000.

“The 1996 Minority Fellowship Grant Preceptor.” Sponsor: Purdue University School of Pharmacy and Pharmacal Sciences. 1996; \$3,500.

“Effect of Bleach/Formaldehyde Reuse on the Removal of Varying Molecular Weight Solutes During High-permeability Hemodialysis.” PI: Meri K. Scott. Co-Investigator: **Bruce A. Mueller**. Sponsor: Fresenius, Inc. USA. 1996, Materiel Support; \$8,000.

“The Effect of Peracetic Acid-Hydrogen Peroxide Reuse on the Removal of Varying Molecular Weight Solutes During High-permeability Hemodialysis.” PI: Meri K. Scott. Co-Investigators: **Bruce A. Mueller** and William R. Clark. Sponsor: Baxter Healthcare Co. 1996, Material Support; \$7,500.

“The Effect of Reuse on the Removal of Vancomycin During High-Permeability Hemodialysis”. PI: Meri K. Scott. Co- Investigators: **Bruce A. Mueller** and William R. Clark. Sponsor: Eli Lilly and Company. 1995, Materiel Support; \$1,500.

“Effect of Enteral Feedings on the Oral Bioavailability of Levofloxacin and Ciprofloxacin.” PI: **Bruce A. Mueller**. Co-Investigators: Donna S. Wall, Steven R. Abel, and Michael A. Kraus. Sponsor: Robert Wood Johnson Foundation. 1995; \$28,000.

“Comparison of Vancomycin Serum Concentrations by FPIA and EMIT.” PI: **Bruce A. Mueller**. Co-Investigators: Sheryl L. Follin and Michael A. Kraus. Sponsor: National Kidney Foundation. 1994; \$4,000.

“Drug Dosing in High Flux Hemodialysis.” PI: **Bruce A. Mueller**. Co-investigator: Meri Kay Scott. Sponsor: Bristol-Myers Squibb. 1994; \$2,000.

“Ofloxacin & Ciprofloxacin Bioavailability with Enteral Feedings.” PI: **Bruce A. Mueller**. Co-Investigator: Steven R. Abel. Sponsor: Robert Wood Johnson Foundation. 1992; \$11,800.

## **Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

“Antibiotic Pharmacokinetics in Acute Renal Failure Patients Receiving Continuous Hemofiltration.” PI: **Bruce A. Mueller**. Co-investigators: William L. Macias, Sheila K. Scarim. Sponsor: National Kidney Foundation of Indiana, Inc. 1992; \$5,000.

“Mucositis Survey.” PI: **Bruce A. Mueller**. Co-Investigators: Elizabeth A. Farrington, Cindy S. Brusko, Thomas H. Wisner. Biomedical Research Support Grant. 1992; \$3,225.

“Pharmacy Affairs Grant.” PI: **Bruce A. Mueller**. Sponsor: Merck, Sharp, & Dohme. 1991; \$150.

“Efficacy and Tolerability of a Polysaccharide-Iron Complex in Chronic Dialysis Patients Receiving Erythropoietin.” Co-PI: **Bruce A. Mueller**, Patrick J. Heffernan. Co-investigators: Steven R. Abel, Douglas R. Maxwell. Sponsor: Central Pharmaceuticals. October 1990 - June 1991; \$28,645.

“Effects of Oral vs. Buccal Piroxicam on the Gastric Mucosa.” Co-PI: **Bruce A. Mueller**, Douglas K. Rex. Co-investigator: D.C. Brater. Sponsor: Zetachron, Inc. November 1989 - December 1990; \$75,000.

“Pneumonias.” **Bruce A. Mueller**, Rodney A. Carter. Grant to write and produce a two-hour videotape for the Drug Therapy Monitoring Certificate Program, Purdue University. Sponsor: Miles Laboratories. 1990; \$15,000.

“Urinary Tract Infections.” **Bruce A. Mueller**, Rodney A. Carter. Grant to produce a two-hour videotape for the Drug Therapy Monitoring Certificate Program, Purdue University. Sponsor: Lederle Laboratories. 1990;

“Biomedical research in clinical practice.” PI: **Bruce A. Mueller**. Sponsor: Biomedical Research Support Grant. 1988; \$1,945.

### **PUBLICATIONS**

1. **Mueller BA**, Klaus J. Insulin syringes - reuse in patients. In: Connor CS, Rumack BH, eds. Drugdex Information System. Denver, CO: Micromedex, Inc., 1987.
2. **Mueller BA**, Klaus J. Morphine dosing in renal failure. In: Connor CS, Rumack BH, eds. Drugdex Information System. Denver, CO: Micromedex, Inc., 1987.
3. **Mueller BA**, Bussey HI, Casto DT, Lowder NK, Sugarek NJ, Cremer KF. Lack of endogenous cross-reactivity with three digitoxin radioimmunoassay in adults with renal insufficiency. Clin Pharm 1988;7:825-828.
4. **Mueller BA**, Talbert RL. Biological mechanisms and cardiovascular effects of omega-3 fatty acids. Clin Pharm 1988;7:795-807.
5. **Mueller BA**, Abel SR. Impact of college of pharmacy-based educational services within the hospital. DICP Ann Pharmacother 1990;24(4):422-425.
6. Cover DL, **Mueller BA**. Ciprofloxacin penetration into human breast milk: A case report. DICP Ann Pharmacother 1990;24(7-8):703-704.
7. Southwood RL, **Mueller BA**, Copley JB. Soft tissue calcification in renal failure. DICP Ann Pharmacother 1990;24(9):855-859.
8. **Mueller BA**, Talbert RL, Tegeler CH, Prihoda TJ. The bleeding time effects of a single dose of aspirin in subjects receiving omega-3 fatty acid dietary supplementation. J Clin Pharmacol 1991;31(2):185-190.
9. Macias WL, **Mueller BA**, Scarim SK. Vancomycin pharmacokinetics in acute renal failure: Preservation of non-renal clearance. Clin Pharmacol Ther 1991;50(6):688-94.

## Bruce A. Mueller, PharmD, FCCP, FASN, FNKF

10. Macias WL, **Mueller BA**, Scarim SK, Robinson M, Rudy DW. Continuous venovenous hemofiltration: An alternative to continuous arteriovenous hemofiltration and hemodiafiltration in acute renal failure. *Am J Kidney Dis* 1991;18(4):451-8.
11. **Mueller BA**, Palmer LM. Diabetic gastroparesis: Erythromycin as a possible treatment. *Indiana Pharmacist*, 1991;72(12):14-18.
12. Wallace CS, **Mueller BA**. Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs. *Ann Pharmacother* 1992;26(2):190-2.
13. **Mueller BA**, Rex DK, Greene P, Figueroa N, Brater DC. A pharmacokinetic and endoscopic comparison of an oral and an experimental buccal piroxicam formulation. *Pharmacotherapy* 1992;12(2):93-97.
14. Clark WR, Murphy MH, Alaka KJ, **Mueller BA**, Pastan SO, Macias WL. Urea kinetics in continuous hemofiltration. *ASAIO Journal* 1992;38(3):M664-M667.
15. Mortazavi P, **Mueller BA**. Erythromycin in gastrointestinal motility disturbances. *Ann Pharmacother* 1992;26(9):1095-97.
16. **Mueller BA**, Scarim SK, Macias WL. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. *Am J Kidney Dis* 1993;21(2):172-9.
17. Perino L, **Mueller BA**. Accuracy of vancomycin serum concentrations in patients with renal failure. *Ann Pharmacother* 1993;27:892-3.
18. Ratulowski K, **Mueller BA**. The use of beta agonists for the treatment of hyperkalemia in patients with renal failure. In: Connor CS, Rumack BH, eds. *Drugdex Information System*. Denver, CO: Micromedex, Inc., 81st edition, 1994.
19. Kernan W, **Mueller BA**. Morphine dosing in renal failure. In: Connor CS, Rumack BH, eds. *Drugdex Information System*. Denver, CO: Micromedex, Inc., 81st edition, 1994.
20. Clark WR, **Mueller BA**, Alaka KJ, Macias WL. A comparison of metabolic control by continuous and intermittent therapies in acute renal failure. *J Am Soc Nephrol* 1994;4:1413-20.
21. **Mueller BA**, Brierton DG, Abel SR, Bowman L. Effect of enteral feeding with Ensure® on the oral bioavailability of ofloxacin and ciprofloxacin. *Antimicrob Agents Chemother* 1994;38:2101-2105.
22. **Mueller BA**, Millheim ET, Farrington EA, Brusko C, Wisner TH. Mucositis management practices for hospitalized patients: National survey results. *J Pain Sympt Management* 1995;10(7):510-20.
23. Macias WL, Murphy MH, Alaka KJ, Clark WR, Miller MH, **Mueller BA**. Impact of the nutritional regimen on protein catabolism and nitrogen balance in patients with acute renal failure. *JPEN* 1996;20:56-62.
24. Bottoms G, Fessler J, Murphey E, Johnson M, Latshaw H, **Mueller BA**, Clark W, Macias W. Efficacy of convective removal of plasma mediators of endotoxic shock by continuous veno-venous hemofiltration. *Shock* 1996;5(2):149-154.
25. Follin SL, **Mueller BA**, Scott MK, Carfagna MA, Kraus MA. Falsely elevated serum vancomycin concentrations in hemodialysis patients. *Am J Kidney Dis* 1996;27:67-74.
26. Clark WR, **Mueller BA**, Kraus MA, Macias WL. Solute control in acute renal failure: Prescription and delivery of adequate extracorporeal therapy. *Semin Dial* 1996;9:133-139.
27. Clark WR, **Mueller BA**, Kraus MA, Macias WL. Solute control by extracorporeal therapies in acute renal failure. *Am J Kidney Dis* 1996;28 (Suppl 3):S21-S27.
28. Robertson KE, **Mueller BA**. Uremic pruritus. *Am J Health-Syst Pharm* 1996;53:2159-70.

## Bruce A. Mueller, PharmD, FCCP, FASN, FNKF

29. Schumock GT, Meek PD, Ploetz PA, Vermeulen LC, Alldredge B, Amsden G, Anderson D, Bednarczyk E, Goodwin SD, Jaber L, Knoppert D, **Mueller BA**, Otto M, Poirier T, Rho J, Scheife R, Smythe M. Economic evaluations of clinical pharmacy services-1988-1995. The Publications Committee of the American College of Clinical Pharmacy. *Pharmacotherapy* 1996;16(6):1188-208.
30. Scott MK, **Mueller BA**, Clark WR. Vancomycin mass transfer characteristics of high-flux cellulose dialyzers. *Nephrol Dial Transplant* 1997 Dec;12(12):2647-53
31. Scott MK, **Mueller BA**, Kraus MA, Carfagna MA, Clark WR, Macias WL. Effects of dialysis membrane on intradialytic vancomycin administration. *Pharmacother* 1997;17(2):256-62.
32. Murphey ED, Fessler JF, Bottoms GD, Latshaw H, Johnson M, **Mueller BA**, Clark WR, Macias WL. Effects of continuous venovenous hemofiltration on cardiopulmonary function in a porcine model of endotoxin-induced shock. *Am J Vet Res* 1997;58:408-13.
33. Clark WR, **Mueller BA**, Kraus MA, Macias WL. Extracorporeal therapy requirements for patients with acute renal failure. *J Am Soc Nephrol* 1997;8:804-12.
34. Clark WR, **Mueller BA**, Kraus MA, Macias WL. Dialysis prescription and kinetics in acute renal failure. *Adv Ren Replace Ther* 1997;4(2) Suppl 1:64-71.
35. Brophy DF, **Mueller BA**. Automated peritoneal dialysis: new implications for pharmacists. *Ann Pharmacother* 1997;31:756-64
36. Kotlyar M, **Mueller BA**: Insulin therapy in chronic ambulatory peritoneal dialysis (Drug Consult). In: Gelman, CR, Rumack BH & Hutchison TA (Eds): Drugdex System. Micromedex, Inc., Englewood, Colorado, 1997.
37. Clark WR, **Mueller BA**, Kraus MA, Macias WL. The role of renal replacement therapy quantification in acute renal failure. *Am J Kidney Dis* 1997;5:S10-S14 (suppl. 4).
38. Isenhower H and **Mueller BA**. Selection of narcotic analgesics for pain associated with pancreatitis. *Am J Health-Syst Pharm* 1998;55:480-6.
39. Clark WR, **Mueller BA**, Kraus MA, Macias WL. Renal replacement therapy quantification in acute renal failure. *Nephrol Dial Transplant* 1998;13(Suppl 6):86-90.
40. Clark WR, **Mueller BA**, Kraus MA, Macias WL. Quantification of creatinine kinetic parameters in patients with acute renal failure. *Kidney Int* 1998;54:554-60.
41. Worland MA, Radabaugh RS, **Mueller BA**. Intraperitoneal thrombolytic therapy for peritoneal dialysis associated peritonitis. *Ann Pharmacother* 1998;32(11):1216-20.
42. Scott MK, **Mueller BA**, Sowinski KM, Clark WR. Dialyzer-dependent changes in solute and water permeability with bleach reprocessing. *Am J Kidney Dis* 1999;33(1):87-96.
43. Benjamin S, **Mueller BA**. Erythema multiforme secondary to amoxicillin/clavulanic acid exposure. *Ann Pharmacother* 1999;33:109-110.
44. Sowinski KM, Abel SR, Clark WR, **Mueller BA**. Effect of gender on the pharmacokinetics of ofloxacin. *Pharmacother* 1999;19:442-446.
45. Clark WR, Leypoldt JK, Henderson LW, **Mueller BA**, Scott MK, Vonesh EF. Quantifying the effect of changes in the hemodialysis prescription on effective solute removal with a mathematical model. *J Am Soc Nephrol* 1999; 10(3):601-609.
46. Clark WR, **Mueller BA**, Scott MK, Bander S. Low-molecular weight protein removal by high-flux dialyzers: basic mechanisms and effect of reprocessing. *Semin Dial* 1999;12(5):349-54.

## Bruce A. Mueller, PharmD, FCCP, FASN, FNKF

47. Brophy DF, Sowinski KM, Kraus MA, Moe SM, Klaunig JE, **Mueller BA**. Small and middle molecular weight solute clearance in nocturnal intermittent peritoneal dialysis. *Perit Dial Int* 1999;19(6):534-539
48. Trujillo TN, Sowinski KM, Venezia RA, Scott MK, **Mueller BA**. Vancomycin assay performance in patients with acute renal failure. *Intensive Care Med* 1999;25:1291-6.
49. Scott MK, **Mueller BA**, Sowinski KM. The effects of peracetic acid-hydrogen peroxide reprocessing on dialyzer solute and water permeability. *Pharmacotherapy* 1999;19(9):1042-9.
50. **Mueller BA**, Scott MK, Sowinski KM, Prag KA. Noni Juice: Hidden potential for hyperkalemia? *Am J Kidney Dis* 2000;35(2):310-12.
51. Kingery JR, Sowinski KM, Kraus MA, Klaunig JE, **Mueller BA**. Vancomycin assay performance in patients with end-stage renal disease receiving hemodialysis. *Pharmacotherapy* 2000; 20:653-656.
52. Scott MK, Kim MA, Kraus MA, **Mueller BA**, Sehra RA, Altemose GT, Sowinski KM. Effect of cisapride on QT interval in patients with end-stage renal disease. *Am J Cardiol* 2000; 86;8:873-5.
53. Sowinski KM, **Mueller BA**, Grabe DW, Manley HJ, Frye RF, Bailie GR, Marx MA. Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. *Am J Kidney Dis* 2001;37(4):766-776.
54. Choe HM, Kim J, Kyung BC, **Mueller BA**. Implementation of the first pharmacist-managed ambulatory care anticoagulation clinic in South Korea. *Am J Health Syst Pharm*. 2002; May 1;59(9):872-4.
55. Lucksiri A, Scott MK, **Mueller BA**, Hamburger RJ, Sowinski KM. CAHP-210 Dialyzer influence on intradialytic vancomycin removal. *Nephrol Dial Transplant* 2002;17:1649-1654.
56. **Mueller BA**, Pasko DA, Sowinski KM. Higher renal replacement therapy dose delivery influences on drug therapy. *Artif Organs* 2003;27(9):808-814.
57. Sowinski KM, Lucksiri A, Kays MN, Scott MK, **Mueller BA**, Hamburger RJ. Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer. *Am J Kidney Dis* 2003;42(2):342-9.
58. Kraft MK, Pasko DA, DePestel DD, Ellis JJ, Peloquin CA, **Mueller BA**. Linezolid clearance during continuous venovenous hemodiafiltration: A case report. *Pharmacotherapy* 2003 Aug;23(8):1071-5.
59. Pasko DA, Mottes TA, **Mueller BA**. Pre dialysis of blood prime in continuous hemodialysis normalizes pH and electrolytes. *Pediatr Nephrol*. 2003 Nov;18(11):1177-83.
60. Kays MB, Overholser BR, **Mueller BA**, Moe SM, Sowinski KM. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. *Am J Kidney Dis* 2003;42:1253-1259.
61. Nakamura AT, Btaiche IF, Pasko DA, Jain JC, **Mueller BA**. In vitro clearance of trace elements via continuous renal replacement therapy. *J Ren Nutr* 2004 Oct;14(4):214-9.
62. Sowinski KM, Cronin DA, **Mueller BA**, Kraus MA. Subcutaneous terbutaline use in chronic kidney disease to reduce potassium concentrations. *Am J Kidney Dis*, 2005;45(6):1040-1045.
63. Overholser BR, Kays MB, Lagvankar S, Goldman M, **Mueller BA**, Sowinski KM. Pharmacokinetics of intravenously administered levofloxacin in men and women. *Pharmacotherapy* 2005;25:1310-8.
64. Taber SS, **Mueller BA**. Drug-associated renal dysfunction. *Critical Care Clinics* 2006;22:357-74.
65. Churchwell MD, Pasko DA, **Mueller BA**. Daptomycin clearance during modeled continuous renal replacement therapy. *Blood Purification* 2006 Nov 16;24(5-6):548-554.

## Bruce A. Mueller, PharmD, FCCP, FASN, FNKF

66. Churchwell MD, **Mueller BA**. Pharmacokinetic issues in patients with chronic kidney disease. *Blood Purification* 2007;25(1):133-8.
67. Mohammad RA, Sweet BV, **Mueller BA**, Perlman RL, Stevenson JG. Outcomes of erythropoietic growth factor interchange program in hospitalized chronic hemodialysis patients. *Hospital Pharmacy* 2007;42:119-125.
68. Laiprasert J, Klein KC, **Mueller BA**, Pearlman MD. Transplacental passage of vancomycin in non-infected term pregnant women. *Obstet Gynecol* 2007;109:1105-10.
69. Decker BS, **Mueller BA**, Sowinski KM. Drug dosing considerations in alternative hemodialysis. *Advances in Chronic Kidney Disease* 2007; Vol 14, No 3 (July):e17-e26.
70. Churchwell MD, Pasko DA, Btaiche IF, Jain J, **Mueller BA**. Trace element removal during in vitro and in vivo continuous hemodialysis. *Nephrology Dialysis Transplantation* 2007;22:2970-2977.
71. Sowinski KM, Magner SJ, Lucksiri A, Scott MK, Hamburger RJ, **Mueller BA**. Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing. *Clin J Am Soc Nephrol* 2008;March:3(2):355-361.
72. Btaiche IF, Mohammad RA, Alaniz C, **Mueller BA**. Amino acid requirements in critically ill patients with acute kidney injury treated with continuous renal replacement therapy. *Pharmacotherapy* 2008;28(5):600-613.
73. Churchwell MD, Pasko DA, Smoyer WE, **Mueller BA**. Enhanced clearance of highly protein-bound drugs by albumin-supplemented dialysate during modeled continuous hemodialysis. *Nephrol Dial Transplant* 2009;24(1):231-8.
74. Scott MK, Shah NA, Vilay AM, Thomas J, Kraus MA, **Mueller BA**. Effects of peri-dialytic oral supplements on nutritional status and quality of life in chronic hemodialysis patients. *J Ren Nutr* 2009; 19(2):145-52.
75. Heung M, **Mueller BA**, Segal JH. Optimizing anemia management in hospitalized patients with end-stage renal disease. *Ann Pharmacother* 2009;43(2):276-82.
76. Pasko DA, Churchwell MD, Btaiche IF, Jain JC, **Mueller BA**. Continuous venovenous hemodiafiltration trace element clearance in pediatric patients: a case series. *Pediatr Nephrol* 2009;24:807-813.
77. Stevenson JM, Patel JH, Churchwell MD, Vilay AM, DePestel DD, Sörgel F, Kinzig M, Jakob V, **Mueller BA**. Ertapenem clearance during modeled continuous renal replacement therapy. *Int J Artif Organs* 2008;12:1027-34.
78. Vilay AM, Churchwell MD, **Mueller BA**: Drug metabolism and nonrenal clearance in acute kidney injury. *Crit Care (London, England)* 2008;12(6):235.
79. Choe HM, Bernstein S, **Mueller BA**, Walker P, Stevenson L, Standiford C. Pharmacist leads primary care team to improve diabetes care. *Am J Health-Syst Pharm* 2009;66(7):622-4.
80. Churchwell MD, **Mueller BA**. Drug dosing during continuous renal replacement therapy. *Seminars in Dialysis* 2009;Mar-April;22(2):185-8.
81. Fleming GM, Salama NN, Eid SK, Cooke KR, **Mueller BA**. Etanercept clearance during an in vitro model of CVVH. *Blood Purification* 2009;28(4):348-353.
82. **Mueller BA**, Smoyer WE. Challenges in developing evidence-based drug dosing guidelines for adults and children receiving renal replacement therapy. *Clin Pharmacol Ther* 2009;86(5):479-482.
83. Salama NN, Segal JH, Churchwell MD, Patel JH, Gao L, Heung M, **Mueller BA**. Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis. *Clin J Am Soc Nephrol* 2009;4(7):1190-4.

**Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

84. Patel JH, Churchwell MD, Seroogy JD, Barriere S, Griro M, **Mueller BA**. Telavancin and hydroxy propyl- $\beta$ -cyclodextrin clearance during continuous renal replacement therapy: An in vitro study. *The International Journal of Artificial Organs* 2009;32(10):745-751.
85. Salama NN, Segal JH, Churchwell MD, Patel JH, Gao L, Heung M, **Mueller BA**. Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients. *Nephrol Dial Transplant* 2010;25:1279-1284.
86. Vilay AM, **Mueller BA**, Haines H, Alten JA, Askenazi DJ. Treatment of methotrexate intoxication with various modes of continuous extracorporeal therapy and glucarpidase: A case report. *Pharmacotherapy* 2010;30(1):53e-58e.
87. Vilay AM, Shah KH, Churchwell MD, Patel JH, DePestel DD, **Mueller BA**. Modeled Dalbavancin Transmembrane Clearance during Intermittent and Continuous Renal Replacement Therapies. *Blood Purification* 2010;30:37-43.
88. Eyler RF, **Mueller BA**. Antibiotic pharmacokinetic and pharmacodynamic considerations in patients with kidney disease. *Adv Chronic Kidney Dis*. 2010 Sep;17(5):392-403.
89. Pasko DA, Churchwell MD, Salama NN, **Mueller BA**. Longitudinal Hemodiafilter Performance in Modeled Continuous Renal Replacement Therapy. *Blood Purification* 2011;32:82-88.
90. Eyler, RF, **Mueller BA**. Antibiotic Dosing in Critically Ill Patients with Acute Kidney Injury. *Nature Reviews Nephrology* 2011;7:226-235.
91. Vilay AM, Griro M, DePestel DD, Sowinski KM, Gao L, Heung M, Salama NN, **Mueller BA**. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. *Crit Care Med*. 2011 Jan;39(1):19-25.
92. **Mueller BA**, Crompton JA, Donovan BJ, Yankalev S, Lamp KC. Safety of daptomycin in patients receiving hemodialysis. *Pharmacotherapy* 2011;31(7):665-672.
93. Matzke GR, Aronoff GR; Atkinson Jr AJ, Bennett WM, Decker BS, Eckardt KU, Golper T, Grabe DW, Kasiske B, Leller F, Kielstein JT, Mehta R, **Mueller BA**, Pasko DA, Schaefer F, Sica DA, Inker LA, Umans JG, Murray P. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney International* 2011;80:1122-37
94. Harder JL, Heung M, Vilay AM, **Mueller BA**, Segal JH. Carbamazepine and the active epoxide metabolite are effectively cleared by hemodialysis followed by continuous venovenous hemodialysis in an acute overdose. *Hemodial Int* 2011;15:412-5.
95. Vilay AM, Griro M, DePestel DD, Sowinski KM, Gao L, Heung M, Salama NN, **Mueller BA**. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. *Crit Care Med* 2011; 39:19-25.
96. Eyler RF, **Mueller BA**. Antibiotic dosing in critically ill patients with acute kidney injury. *Nature Reviews Nephrology* 2011;7:226-235
97. Ghannoum M, Nolin TD, Lavergne V, Hoffman RS, Bunchman TE, Burdmann EA, Calello DP, Dalhoff KP, Dargan PI, Goldfarb DS, Jurrlink DN, Kielstein JT, Laliberté M, Lavonas EJ, Li Y, Liu KD, Maclaren R, Mégarbane B, Mowry JB, **Mueller BA**, Roberts DM, Winchester JF. Blood purification in toxicology: nephrology's ugly duckling. *Adv Chronic Kidney Dis* 2011;18(3):160-6.
98. **Mueller BA**, Scoville BA. Adding to the armamentarium: Antibiotic dosing in extended dialysis. *Clin J Am Soc Nephrol* 2012;7:373-5.
99. Eyler RF, Klein KC, **Mueller BA**. The pharmacokinetics of oseltamivir and oseltamivir carboxylate in a critically ill pediatric patient receiving extracorporeal membrane oxygenation and continuous venovenous hemodialysis. *J Pediatr Pharmacol Ther* 2012;17(2):173-176.

## Bruce A. Mueller, PharmD, FCCP, FASN, FNKF

100. Eyler RF, Heung M, Pleva M, Sowinski KM, Park PK, Napolitano LM, **Mueller BA**. The pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill subjects receiving CVVHD and/or ECMO. *Pharmacotherapy* 2012 32(12):1061-9.
101. Matzke GR, Aronoff GR, Atkinson Jr. AJ, Bennett WM, Decker BS, Eckardt K-U, Golper T, Grabe DW, Kasiske B, Keller F, Kielstein JT, Mehta R, **Mueller BA**, Pasko DA, Schaefer F, Sica DA, Inker LA, Umans JG, Murray P. Drug dosing consideration in patients with acute and chronic kidney disease - A clinical update from *Kidney Disease: Improving Global Outcomes (KDIGO)*. *Nieren- und Hochdruckkrankheiten* 2012;41(2):45-61.
102. Butterfield JM, **Mueller BA**, Patel N, Cardone KE, Grabe DW, Salama NN, Lodise TP. Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis. *Antimicrob Agents Chemother* 2013;57(2): 864-72.
103. Scoville BA, **Mueller BA**. Medication dosing in critically ill patients with acute kidney injury treated with renal replacement therapy. *Am J Kidney Dis* 2013;61:490-500.
104. Kelley KA, Kuba SE, Mason HL, **Mueller BA**, Plake KS, Seaba HH, Soliman SR, Sweet BV, Yee G. Re-envisioning assessment for accreditation: Considerations for the ACPE standards revision process and the academy. *Am J Pharm Educ* 2013;77(7):article 141.
105. Stevenson JM, Heung M, Vilay AM, Eyler RF, Patel C, **Mueller BA**. In vitro glucose kinetics during continuous renal replacement therapy: implications for caloric balance in critically ill patients. *Int J Artif Organs* 2013;36(12):861-8. PMID: 24366837
106. Eyler R, Vilay AM, Nader A, Heung M, Pleva M, Sowinski KM, DePestel DD, Sörgel F, Kinzig M, **Mueller BA**. Pharmacokinetics of Ertapenem in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD) or Hemodiafiltration (CVVHDF). *Antimicrob Agent Chemother* 2014;58(3):1320-6.
107. Lewis SJ, **Mueller BA**. Antibiotic underdosing in critically ill patients receiving CRRT: Underdosing is overprevalent. *Semin Dial* 2014;27(5):441-445. PMID: 25204875
108. Bouchard J, Roberts DM, Ouellet G, Decker BS, **Mueller BA**, Desmeules S, Ghannoum M. Principles and operational parameters to optimize poison removal with extracorporeal treatments. *Semin Dial* 2014;27(4):371-80. PMID: 24824059
109. Jamal JA, **Mueller BA**, Choi GYS, Lipman J, Roberts JA. How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy? *Diagnostic Microbiology and Infectious Disease* 2015;82(1):92-103.
110. Mei JP, Ali-Moghaddam, A, **Mueller BA**. Survey of pharmacist's antibiotic dosing recommendations for sustained low-efficiency dialysis. *Int J Clin Pharmacy* 2015;38(1):127-34.
111. Lewis SJ, Switaj L, **Mueller BA**. Tedizolid Adsorption and Transmembrane Clearance during In vitro Continuous Renal Replacement Therapy (CRRT). *Blood Purification* 2015;40(1):66-71.
112. Lewis SJ, **Mueller BA**. Antibiotic Dosing in Patients with Acute Kidney Injury: "Enough But Not Too Much". *J Intens Care Med* 2016;31(3):164-76.
113. Kempke AP, Leino AS, Daneshvar F, Lee JA, **Mueller BA**. Antimicrobial doses in continuous renal replacement therapy: a comparison of dosing strategies. *Crit Care Research Practice* 2016. Article ID 3235765. DOI: 10.1155/2016/3235765. PMID: 27433357
114. Fleming GM, **Mueller BA**. "In Through the Out Door": Led Zeppelin and Drug Administration in CRRT. *Pediatr Crit Care Med* 2016;17(4):373-4. PMID: 27043905 (Editorial)



## Bruce A. Mueller, PharmD, FCCP, FASN, FNKF

115. Gharibian KN, **Mueller BA**. Fluconazole Dosing Predictions in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy: A Monte Carlo Simulation Approach. *Clin Neph* 2016;86(7):43-50. DOI: 10.5414/CN108824 PMID: 27251341
116. Shaw A, Chaijamorn W, **Mueller BA**. We underdose antibiotics in patients on CRRT. *Semin Dial*. 2016;29(4):278-80. DOI: 10.1111/sdi.12496. Epub 2016 Apr 15. PMID: 27082510
117. Lewis SJ, Kays MB, **Mueller BA**. Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy. *J Clin Pharmacol* 2016;56(10):1277-87. DOI: 10.1002/jcph.727. Epub 2016 Apr 8.
118. Eschenauer GA, Lam SW, **Mueller BA**. Dose Timing of Aminoglycosides in Hemodialysis Patients: A Pharmacology View. *Semin Dial* 2016;29(3):204-13. DOI: 10.1111/sdi.12458. Epub 2016 Jan 16 Review.
119. Sweet BV, Madeo A, Fitzgerald M, House J, Pardee M, Zebrack B, Sweier D, Hornyak J, Arslanian-Engoren C, Mattison D, Dubin L, Stojan J, **Mueller BA**. Moving from individual roles to functional teams: A semester-long course in case-based decision making. *J Interprof Educ Practice* 2017;7:11-6.
120. Shi J, Wang X, Eyler RF, Liang Y, Liu L, **Mueller BA**, Zhu HJ. Association of oseltamivir activation with gender and carboxylesterase 1 genetic polymorphisms. *Basic & Clinical Pharmacology & Toxicology* 2016;119(6):555-561. DOI: 10.1111/bcpt.12625. PMID: 27228223
121. Lewis SJ, Chaijamorn W, Shaw A, **Mueller BA**. In silico Trials Using Monte Carlo Simulation to Evaluate Ciprofloxacin and Levofloxacin Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy. *Ren Replace Ther* 2016, 2:45. DOI: 10.1186/s41100-016-0055-x
122. Chaijamorn W, Shaw AR, Lewis SJ, **Mueller BA**. Ex vivo Ceftolozane/Tazobactam Clearance During Continuous Renal Replacement Therapy. *Blood Purification* 2017;44(1):16-23. DOI: 10.1159/000455897
123. Shaw AR, **Mueller BA**. Influence of Effluent Rate on Antibiotic Pharmacodynamic Target Attainment Rates in Patients Receiving CRRT: Does effluent flow matter? *Advances in Chronic Kidney Disease* 24(4):219-227
124. Gharibian KN, Murthy V, **Mueller BA**. Influence of hemodialysis on regadenoson clearance in an in vitro hemodialysis model. *J Nucl Cardiol* 2018 Feb;25(1):234-239 PMID: 27632986, DOI: 10.1007/s12350-016-0667-0
125. Heung M, **Mueller BA**. Prevention of Hypophosphatemia During Continuous Renal Replacement Therapy – An Overlooked Problem. *Semin Dial* 2018; Feb 5. DOI: 10.1111/sdi.12677. PMID: 29405468
126. Sargel C, Aboud M, Forster A, Langman L, Tansmore J, **Mueller B**, Smoyer W, Auletta J. Intravenous ribavirin for parainfluenza and respiratory syncytial virus lower respiratory tract infection in an infant receiving extracorporeal membrane oxygenation and continuous renal replacement therapy. *J Pediatr Pharmacol Ther*. 2018 Jul-Aug;23(4):337-342
127. Scoville BA, Vulaj V, **Mueller BA**, Annich GM, Wagner DS. Acetaminophen Clearance During Ex Vivo Continuous Renal Replacement Therapies. *J Artif Organs* 2018; 21(2):215-219
128. Shaw AR, Chaijamorn W, Clark JS, **Mueller BA**. Preparation times and costs for various solutions used for continuous renal replacement. *Am J Health-System Pharm* 2018, 75 (11) 808-815; DOI: 10.2146/ajhp160741
129. Lewis SJ, **Mueller BA**. Development of a vancomycin dosing approach for critically ill patients receiving hybrid hemodialysis using Monte Carlo Simulation. *SAGE Open Med* 2018, 11;6:2050312118773257. doi: 10.1177/2050312118773257
130. Jang SM, Hough G, **Mueller BA**. Ex vivo Rezafungin Adsorption and Clearance during Continuous Renal Replacement Therapy. *Blood Purification* 2018, 46(3), 214-219; DOI: [10.1159/000489212](https://doi.org/10.1159/000489212)

**Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

131. Jang SM, Clark JS, **Mueller BA**. Update on preparation of solutions for continuous renal therapy. Am J Health-System Pharm 2018, 75(13), 931-932; DOI: <https://doi.org/10.2146/ajhp180172>

**Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

132. Jang SM, Gharibian KN, Lewis, SJ, Fissell WH, Tolwani AT, **Mueller BA**. A Monte Carlo Simulation Approach for Beta-lactam Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy. *J Clin Pharmacol* 2018; 10.1002/jcph.1137
133. Barreto EF, **Mueller BA**, Kane-Gill SL, Rule AD, Steckelberg JM. Beta-lactams: The competing priorities of nephrotoxicity, neurotoxicity, and stewardship. *Ann Pharmacother*. 2018 Nov;52(11):1167-1168.
134. Scoville BA, Segal JH, Salama NN, Heung M, Bleske B, Eyler RF, **Mueller BA**. Single Dose Oral Ranolazine Pharmacokinetics in Patients Receiving Maintenance Hemodialysis. *Renal Failure* 2019;41:118-125.
135. Jang SM, Pai MP, Shaw AR, **Mueller BA**. Antibiotic exposure profiles in trials comparing intensity of continuous renal replacement therapy. *Crit Care Med*. 2019 Nov;47(11):e863-e871. doi: 10.1097/CCM.0000000000003955. PMID: 31397714
136. Nigwekar SU, Barton Pai A, **Mueller B**, Dean MC, Costello G, Sherman CR. Impact of hemodialysis on the concentrations of sodium and potassium during infusion of sodium thiosulfate using an in vitro hemodialysis model. *PLoS ONE* 2019;14(11):e0224767.
137. Crass RL, Rodvold KA, **Mueller BA**, Pai MP. Renal Dosing of Antibiotics: Are We Jumping the Gun? *Clin Infect Dis* 2019;68:1596-1602.
138. Rybak MJ, Lodise TP, Bradley JS, Liu C, **Mueller BA**, Pai MP, Wong-Beringer A, Rotschafer JC, Rodvold KA, Maples HD, Lomaestro B. Therapeutic monitoring of vancomycin: A revised consensus guideline and review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists. *Am J Health-Syst Pharm* 2020;77(11):835-864. doi: 10.1093/ajhp/zxaa036. PMID: 32191793
139. Jang SM, Lewis SJ, **Mueller BA**. Harmonizing antibiotic regimens with renal replacement therapy. *Expert Review of Anti-infective Therapy* 2020;18:887-895.  
<https://www.tandfonline.com/doi/full/10.1080/14787210.2020.1764845>
140. Rybak MJ, Lodise TP, Bradley JS, Liu C, **Mueller BA**, Pai MP, Wong-Beringer A, Rotschafer JC, Rodvold KA, Maples HD, Lomaestro BM. Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. *Pharmacotherapy*. 2020 Apr;40(4):363-367.
141. Eyler R, **Mueller B**. Misdosing: More common than you think. *Drug Topics* October 7,2020.  
<https://www.drugtopics.com/view/misdosing-more-common-than-you-think>
142. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, **Mueller BA**, Pai MP, Beringer AW, Rodvold KA, Maples HD. Questions on vancomycin dosing. *Clin Inf Dis* 2020 <https://doi.org/10.1093/cid/ciaa1775>
143. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, **Mueller BA**, Pai MP, Beringer AW, Rodvold KA, Maples HD., Validity of 2020 vancomycin consensus guidelines and further guidance for practical application, *American Journal of Health-System Pharmacy*, 2021;, zxab123, <https://doi.org/10.1093/ajhp/zxab123>
144. Gharibian K, Lewis S, Heung M ,Segal J, Salama N, **Mueller B**. Telavancin Pharmacokinetics in Patients with Chronic Kidney Disease Receiving Haemodialysis. *J Antimicrob Chemother* 2021, dkab370, <https://doi.org/10.1093/jac/dkab370>
145. Demirjian SD, Teixeira JP; **Mueller BA**, Rodriguez WA, Yessayan LT, Bowman BT, Gladish RD; Aragon M. Optimizing Kidney Replacement in Critical Care: SLED Can Play a Bigger Role in the ICU. *SLED Therapy Update, Nephrology Times*, 2021;13(3).

## Bruce A. Mueller, PharmD, FCCP, FASN, FNKF

146. Demirjian SD, Teixeira JP; **Mueller BA**, Rodriguez WA, Yessayan LT, Bowman BT, Gladish RD; Aragon M. Tablo Hemodialysis System: Utilizing Adaptive Dialysis to Address the Challenges of ICU Kidney Replacement Therapy. SLED Therapy Update, Nephrology Times, 2021;13(3).
147. Jang SM, Yessayan L, Dean M, Costello G, Katwaru R, **Mueller BA**. Imipenem/Relebactam Ex Vivo Clearance during Continuous Renal Replacement Therapy. Antibiotics. 2021; 10(10):1184.  
<https://doi.org/10.3390/antibiotics10101184>
148. Jang SM, Shaw AR, **Mueller BA**. Size Matters: The Influence of Patient Size on Antibiotics Exposure Profiles in Critically Ill Patients on Continuous Renal Replacement Therapy. Antibiotics 2021;10:1390.  
<https://doi.org/10.3390/antibiotics10111390>
149. Hudson JQ, Maxson R, Barreto EF, Cho K, Condon AJ, Goswami E, Moon J, **Mueller BA**, Nolin TD, Nyman H, Vilay AM, Meaney CJ. Education Standards for Pharmacists Providing Comprehensive Medication Management in Outpatient Nephrology Settings. Kidney Medicine 2022.  
[DOI:https://doi.org/10.1016/j.xkme.2022.100508](https://doi.org/10.1016/j.xkme.2022.100508)

### BOOK

1. Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, **Mueller BA**, Pasko DA, Smoyer WE. (2007). Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. (5th ed.) Philadelphia: American College of Physicians.

### BOOK CHAPTERS

1. **Mueller BA**, Macias WL. Acute Renal Failure, in DiPiro JT, Talbert RL, Hayes PE, Yee GC, Posey LM (eds): Pharmacotherapy: A Pathophysiologic Approach, 3rd ed. Appleton & Lange, Stamford, CT, 1996.
2. **Mueller BA**, Abel SR. Effect of Disease on Drug Disposition, in Zimmerman T, Kooner K, Sharir M (eds): Textbook of Ocular Pharmacology. 1st ed. Raven Press, New York, 1997.
3. Abel SR, Buss WF, **Mueller BA**. Effect of Age on Drug Disposition, in Zimmerman T, Kooner K, Sharir M (eds): Textbook of Ocular Pharmacology. 1st ed. Raven Press, New York, 1997.
4. **Mueller BA**. Acute Renal Failure, Critical Care Module, in Pharmacotherapy Self-Assessment Program 3rd edition (PSAP III). Lake K, ed. Kansas CiMO: American College of Pharmacy, 1998.
5. **Mueller BA**, Macias WL. Acute Renal Failure, in DiPiro JT, Talbert RL, Hayes PE, Yee GC, Posey LM (eds): Pharmacotherapy: A Pathophysiologic Approach, 4th ed. Prentiss Hall, 1999.
6. Clark WR, Kraus MA, **Mueller BA**. Problems of solute removal in Continuous Renal Replacement Therapy, in Complications of Dialysis - Recognition and Management, 1st ed., edited by Mehta RL, Lemiere N, Marcel Dekker, New York 2000.
7. **Mueller BA**. Acute Renal Failure, in DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds): Pharmacotherapy: A Pathophysiologic Approach, 5th Ed. McGraw-Hill, New York, 2002.
8. **Mueller BA**, Kraus MA, Ronco C and Clark WR. Considerations in the management of patients with acute renal failure. pages 1181-1202 in: Replacement of Renal Function by Dialysis. Hörl, W.H.; Koch, K.M.; Lindsay, R.M.; Ronco, C.; Winchester, J.F. (Eds.) 5th edition, 2004, XXI Kluwer Academic Publishers.
9. **Mueller BA**. Acute Renal Failure in DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds): Pharmacotherapy: A Pathophysiologic Approach, 6th Ed. McGraw-Hill, New York, 2005.
10. **Mueller BA**. Acute Renal Failure in Wells BG, DiPiro JT, Schwinghammer TL, Hamilton CW. Pharmacotherapy Handbook., 6th Edition. McGraw-Hill, New York, 2005.

## Bruce A. Mueller, PharmD, FCCP, FASN, FNKF

11. Sowinski KM, **Mueller BA**. Drug Dosing in Patients with Acute Kidney Injury or Receiving Renal Replacement Therapy. In: Ronco C, Bellomo R, Kellum J. (Eds.) *Critical Care Nephrology*, 2nd edition. Elsevier: Philadelphia, PA, 2008.
12. Vilay AM, **Mueller BA**. Drug Dosing in Patients with Acute Kidney Injury and Receiving Renal Replacement Therapy In: Achim Jorres, Claudio Ronco, and John Kellum, eds. *Management of Acute Kidney Problems*, 1st ed. Heidelberg, Germany: Springer Verlag 2010:241-252.
13. Jang SM, **Mueller BA**. Dosing Considerations for Patients with AKI and CRRT. *Renal/Pulmonary Critical Care Module in Critical Care Self-Assessment Program (CCSAP)*. Lenexa, KS: American College of Clinical Pharmacy, 2017.
14. Jang SM, **Mueller BA**. Drug Dosing In Acute Kidney Injury. In: *Handbook of Critical Care Nephrology*. Philadelphia:Wolters Kluwer 2021.

### LETTERS

1. **Mueller BA**, Bussey HI, Casto DT. Comment: Unusual digoxin concentrations. *Drug Intell Clin Pharm* 1989;23(1):93-94.
2. **Mueller BA**, Talbert RL, Tegeler CH. Comparative effects of omega-3 fatty acids in men and women. *Clin Pharm* 1989;8(5):328-329.
3. **Mueller BA**, Cover DL. Comment: Ciprofloxacin excretion into breast milk. *DICP: Ann Pharmacother* 1990;24:1122.
4. Brierton DG, **Mueller BA**, Scarim SK, Macias WL. Lidocaine in continuous venovenous hemofiltration. *Crit Care Med* 1992;20(10):1498-9.
5. Macias WL, **Mueller BA**, Scarim SK. Vancomycin levels and acute renal failure: Reply. *Clin Pharmacol Ther* 1992;52:570-71
6. **Mueller BA**, Clark WR, Kraus MA, Macias WL. Comment: Vancomycin and tobramycin continuous hemofiltration clearance methodologies. *Ann Pharmacother* 1993;27:1285-86.
7. **Mueller BA**, Abel SR, Brierton DG. Fluoroquinolone bioavailability in patients receiving nutritional supplements. *Am J Health-Syst Pharm* 1995;52:892-93.
8. **Mueller BA**, Millheim ET. Pharmaceutical aspects of mucositis mouthwash mixtures. *Am J Health-Syst Pharm* 1995;52:2596-97.
9. **Mueller BA**, Scott MK, Clark WR. More information on vancomycin clearance by new hemodialysis membranes. *Am J Health Syst Pharm* 1996;53:1339-40.
10. Brophy DF, **Mueller BA**. Vancomycin removal by plasmapheresis. *Ann Pharmacother* 1996;30:1038.
11. Robertson KE, **Mueller BA**. Potentially toxic self-treatment of uremic pruritus with topical pyrethroid insecticides. *Ann Pharmacother* 1997;31:120-121.
12. **Mueller BA**, Carlstedt BC. Pharmacy-buzzword bingo. *Am J Health-Syst Pharm* 1999;56:2464.
13. Sowinski KM, **Mueller BA**. Hyperkalaemia and apple juice. *Lancet* 2001;358:841-2.
14. **Mueller BA**, Pasko DA, Sowinski KM. Ofloxacin clearance during continuous hemofiltration. *Am J Kid Dis* 2003;42:1326-1328.

## Bruce A. Mueller, PharmD, FCCP, FASN, FNKF

15. Churchwell, MD, Btaiche IF, Pasko DA, **Mueller BA**. An understanding of trace metal physiology as an aid to interpretation of clearance studies by artificial organs. *Nephrol Dial Transplant* 2008; 23:1462-1463.
16. Scoville BA, Heung M, **Mueller BA**. Re: Hemofiltration circuit use beyond 72 hours in pediatric continuous renal replacement therapy. *Int J Artif Organs*. 2012; 35(11):1025.
17. Vilay AM, **Mueller BA**. Intradialytic oral nutritional supplements improve quality of life. [Letter] *Am J Kidney Dis* 2013 Feb; 61(2):349.
18. Scoville BA, DeLott LB, Trobe JD, **Mueller BA**. Ethambutol optic neuropathy in a hemodialysis patient receiving guideline-recommended doses. *J Neuroophthalmol*. 2013;33(4):421-3.
19. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, **Mueller BA**, Pai MP, Wong-Beringer A, Rodvold KA, Maples HD. Questions on vancomycin dosing. *Clin Infect Dis* 2020 Nov 26;ciaa1775. doi: 10.1093/cid/ciaa1775.
20. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, **Mueller BA**, Pai MP, Wong-Beringer A, Rodvold KA, Maples HD. Validity of 2020 vancomycin consensus recommendations and further guidance for practical application. *Am J Health-Syst Pharm* 2021 78:1364-7.

### ABSTRACTS

1. **Mueller BA**, Bussey HI, Casto DT, Lowder NK, Sugarek NJ. Digitoxin-like immunoreactive substance in adults with renal insufficiency. *Pharmacother* 1988;8:128.
2. **Mueller BA**, Talbert RL, Tegeler CH. Bleeding time effects of aspirin in subjects ingesting an omega-3 fatty acid enriched diet. *Chest* 1989;96(2):145S.
3. Rudy DW, Macias WL, **Mueller BA**, Scarim SK. Preservation of non-renal vancomycin clearance in acute renal failure. *J Am Soc Nephrol* 1990;1:324.
4. **Mueller BA**, Abel SR. Economic and clinical impact from the provision of educational services by a hospital pharmacy department. *International Pharmaceutical Abstracts* 1990;27(3):2702123.
5. **Mueller BA**, Figueroa N, Brater DC, Greene P, Rex DK. Pharmacokinetics and endoscopic effects of oral vs. buccal piroxicam. *Clin Pharmacol Ther* 1991;49:173.
6. Macias WL, **Mueller BA**, Scarim SK, Robinson M, Rudy DW. Continuous venous-venous hemofiltration (CVVH): An alternative to CAVH in the management of ARF. *Am J Kidney Dis* 1991;17:A15.
7. **Mueller BA**, Scarim SK, Macias WL. Imipenem pharmacokinetics in patients with acute renal failure (ARF) receiving continuous venovenous hemofiltration (CVVH). *Pharmacother* 1991;11(3):269.
8. Scarim SK, **Mueller BA**, Macias WL. Preservation of the non-renal clearance of vancomycin in patients with acute renal failure (ARF) treated with continuous venovenous hemofiltration (CVVH). *Pharmacother* 1991;11(3):269.
9. Scarim SK, Macias WL, **Mueller BA**. Establishment of a continuous venovenous hemofiltration (CVVH) drug dosing service. *International Pharmaceutical Abstracts*. 1992;29:46, abstract 2900130.
10. Heffernan PJ, **Mueller BA**, Maxwell DR, Abel SR. Efficacy and tolerability of a polysaccharide iron complex in dialysis patients receiving erythropoietin. *International Pharmaceutical Abstracts*. 1992;29:137, abstract 2900539.
11. Clark WR, Alaka KJ, Murphy MH, **Mueller BA**, Macias WL. Quantitative comparison of intermittent vs continuous therapy of acute renal failure. *National Kidney Foundation Annual Meeting*, November 15, 1992.

## Bruce A. Mueller, PharmD, FCCP, FASN, FNKF

12. Macias WL, **Mueller BA**, Scarim SK. Continuous Venovenous Hemofiltration (CVVH): Experience in 50 critically ill patients with renal failure. *Am J Kidney Dis* 1992;19:A9.
13. Macias WL, Murphy MH, Alaka KJ, Clark WR, **Mueller BA**. Predictors of urea appearance rate in patients with acute renal failure. *Pharmacother* 1992;12(6):504-5.
14. Macias WL, **Mueller BA**, Kraus MA, Clark WR. Management of refractory septic shock with continuous venovenous hemofiltration (CVVH). *Trans Am Soc Artif Intern Organs* 1993;39:95.
15. Clark WR, Alaka KJ, **Mueller BA**, Macias WL. Comparison of metabolic control achieved by intermittent vs. continuous renal replacement therapy in patients with acute renal failure. *Trans Am Soc Artif Intern Organs* 1993;39:95.
16. **Mueller BA**, Abel SR, Birk CW, Wisner TH. Implementation of a residency seminar series: contemporary topics in pharmacy. *International Pharmaceutical Abstracts*, 1993;30,254.
17. Bowman L, Ferrari MD, **Mueller BA**. Lack of late dissociation of digoxin fab fragment complex in a patient with chronic renal failure. *International Pharmaceutical Abstracts*, 1993, 30, 225.
18. Clark WR, **Mueller BA**. Hemofiltration, urea, catabolic, ultrafiltration, azotemia. *Midwest Meeting of American Federation of Clinical Research*, 1993.
19. Clark WR, Kraus MA, Alaka KJ, **Mueller BA**, Macias WL. A computer-based model for the prediction of extracorporeal therapy requirements in acute renal failure. *American Federation for Clinical Research Meeting*, 1993.
20. Clark WR, Kraus MA, Alaka KJ, **Mueller BA**, Macias WL. Prediction of therapy requirements in continuous venovenous hemofiltration. *Am J Kidney Dis* 1993;22:A2.
21. **Mueller BA**, Brierton DG, Abel SR, Bowman L. Effect of enteral feeding with ensure on the oral bioavailability of ofloxacin and ciprofloxacin. *Pharmacother* 1993;13:674
22. Murphey E, Bottoms G, Fessler J, **Mueller BA**, Clark WR, Macias WL. A swine model of endotoxin induced shock: time-limited step-graded infusion. *Shock Supplement to Vol. 1*, p 34, 1994.
23. Macias WL, Alaka K, Clark W, **Mueller BA**, Miller M. Nutritional status may predict outcome for critically ill patients undergoing continuous hemofiltration. *J Am Soc Nephrol* 1994; 5:497.
24. Clark W, **Mueller BA**, Alaka K, Kraus M, Macias WL. Establishing extracorporeal therapy equivalence on acute renal failure. *J Am Soc Nephrol* 1994;5:411.
25. **Mueller BA**, Millheim ET, Farrington EA, Brusko C, Wisner TH. Use of compounded mouthwash mixtures and mouthcare products in mucositis prophylaxis and treatment: National survey results. *Pharmacother* 1995;15:111.
26. **Mueller BA**, Millheim ET, Farrington EA, Brusko C, Wisner TH. Oral candidiasis and mucocutaneous herpes simplex virus (MHSV) prophylaxis and treatment practices in oncology and bone marrow transplant patients: National mucositis survey results. *Pharmacother* 1995;15:111.
27. Bottoms G, Fessler J, Murphey E, Johnson M, Latshaw H, **Mueller B**, Clark W, Macias W. Efficacy of selective removal of plasma mediators of endotoxic shock by continuous veno-venous hemofiltration. *Shock* 1995;3(supp):48.
28. Murphey E, Fessler J, Bottoms, Johnson M, Latshaw H, **Mueller B**, Clark W, Macias W. Continuous venovenous hemofiltration as a potential therapy for endotoxic shock: The effects of CVVH on cardiopulmonary indices. *Shock* 1995;3(supp):53.

## Bruce A. Mueller, PharmD, FCCP, FASN, FNKF

29. Clark WR, Scott MK, **Mueller BA**, Kraus M, Macias WL. Mass transfer characterization of vancomycin removal by high-flux cellulosic hemodialysis. *J Am Soc Nephrol* 1995;6:486.
30. Clark WR, **Mueller BA**, Kraus M, Macias WL. Treatment of volume overload in patients with acute renal failure by intermittent hemodialysis. *J Am Soc Nephrol* 1995;6:485.
31. Follin SL, Mueller, BA, Kraus MA, Scott MK, Carfagna MA. Falsely-elevated vancomycin serum concentrations in patients receiving conventional hemodialysis. *International Pharmaceutical Abstracts* 1995;32:2371 (abstract #3213178).
32. Scott MK, Macias WL, Kraus MA, Carfagna MA, **Mueller BA**. Intradialytic vancomycin administration: Dialysis membrane effects. *International Pharmaceutical Abstracts* 1995;32:2374 (abstract #3213192).
33. Wall DS, Bear S, **Mueller BA**. Pharmacokinetics of ceftazidime and ciprofloxacin in a patient receiving continuous venovenous hemofiltration (CVVH). *International Pharmaceutical Abstracts* 1995;32:2374 (abstract #3213193).
34. Plesek SR, Siefers SR, Wall DS, **Mueller BA**, Sowinski KM. Fluconazole pharmacokinetics in a patient receiving continuous venovenous hemofiltration. *International Pharmaceutical Abstracts* 1996;33:(abstract #3313633).
35. Clark WR, **Mueller BA**, Kraus MA, Trujillo TN, Macias WL. Estimation of lean body mass by creatinine kinetics in critically ill patients with acute renal failure. *J Am Soc Nephrol* 1996;7(9):1369.
36. Clark WR, Trujillo TN, **Mueller BA**, Kraus MA, Macias WL. Renal replacement therapy utilization in acute renal failure. *J Am Soc Nephrol* 1996;7(9):1370.
37. Clark WR, **Mueller BA**, Kraus MA, Macias WL, Trujillo TN. Factors affecting outcome in critically ill patients with acute renal failure. *J Am Soc Nephrol* 1996;7(9):1404.
38. Scott MK, **Mueller BA**, Clark WR. Effect of peracetic acid-hydrogen peroxide reprocessing on permeability properties of high flux cellulosic hemodialyzers. *J Am Soc Nephrol* 1996;7(9):1419.
39. Sowinski KM, Abel SR, Clark WR, **Mueller BA**. Effect of gender on relative oral bioavailability of ciprofloxacin and ofloxacin when administered with an enteral feeding product. *Pharmacother* 1997;18:1112.
40. Kingery JR, Kraus MA, Sowinski KM, Klaunig JE, **Mueller BA**. Vancomycin assay performance in patients with end-stage renal disease receiving hemodialysis with a high-flux cellulose triacetate dialyzer. *Pharmacother* 1997;17:1098.
41. Hardwick LL, Sowinski KM, **Mueller BA**. Chloramphenicol removal by continuous venovenous hemofiltration (CVVH). *International Pharmaceutical Abstracts* 1997;34:2239.
42. Brophy DF, Sowinski KM, Kraus, MA, Clark WR, Moe SM, Klaunig JE, **Mueller BA**. Peritoneal dialytic clearance of small and middle molecular weight solutes in automated peritoneal. *Pharmacotherapy* 1997;17:191
43. Scott MK, **Mueller BA**, Clark WR. The effects of bleach reprocessing on solute and water permeability of high-flux hemodialyzers. *J Am Soc Nephrol* 1997;8:172.
44. Clark WR, Leypoldt JK, Henderson LW, Sowinski KM, Scott MK, **Mueller BA**, Vonesh EF. Effect of changes in dialytic frequency, duration and flow rates on solute kinetics and effectiveness clearances. *J Am Soc Nephrol* 1997; 8:280.
45. Scott MK, **Mueller BA**, Clark WR. The effects of bleach reprocessing on solute and water permeability of high-flux hemodialyzers. *Blood Purification* 1997;15:7-8.



**Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

46. Clark WR, Leypoldt JK, Henderson LW, Sowinski KM, Scott MK, **Mueller BA**, Vonesh EF. Effect of changes in dialytic frequency, duration and flow rates on solute kinetics and effectiveness clearances. *Blood Purification* 1997;15:8-9.
47. Scott MK, Sowinski KM, **Mueller BA**. An AUC approach for estimating cumulative clearance loss of high-flux hemodialyzers reprocessed fifteen times with peracetic acid-hydrogen peroxide. *Pharmacotherapy* 1998;18:1152-53.
48. Scott MK, **Mueller BA**, Sowinski KM. Effect of PAHP (Peracetic acid-hydrogen peroxide) dialyzer reuse on drug and solute removal. *Pharmacotherapy* 1998;18:1176.
49. Trujillo TN, Venezia RA, Sowinski KM, Clark WR, Scott MK, **Mueller BA**. Comparison of fluorescence polarization immunoassays and enzyme multiplied immunoassay technique (EMIT) assay for the determination of vancomycin serum concentrations in patients with acute renal failure undergoing continuous venovenous hemofiltration. *Pharmacotherapy* 1998;18:1153.
50. Grabe DW, Marx MA, **Mueller BA**, Manley HJ, Bailie GR. Cefazolin pharmacokinetics in hemodialysis patients. *Pharmacotherapy* 1999;19(4):493.
51. Shah NA, **Mueller BA**, Thomas JT, Kraus MA, Scott MK. Effects of supplemental enteral nutrition on nutritional status and quality of life in ESRD patients receiving hemodialysis. *J Am Soc Nephrol* 1999;10:303A.
52. Scott MK, Sowinski KM, **Mueller BA**. Peracetic acid-hydrogen peroxide reprocessing: the effects on dialyzer solute and water permeability. *Pharmacotherapy* 1999;19(9):1042-49.
53. Kim MA, Sowinski KM, Kraus MA, Sehra R, Altemose GT, **Mueller BA**, Scott MK. Effect of cisapride discontinuation on QT interval in patients with ESRD. *Pharmacotherapy* 1999;19(10):1209.
54. Marx MA, Sowinski KM, **Mueller BA**, Grabe HJ, Manley HJ, Bailie GR. Dialytic cefazolin removal can be estimated by urea reduction ratio in high efficiency and high-flux hemodialysis. *J Am Soc Nephrol* 1999;10:334A.
55. Sowinski KM, **Mueller BA**, Grabe DW, Manley HJ, Bailie GR, Marx MA. Effect of hemodialyzer type on cefazolin pharmacokinetics. *J Am Soc Nephrol* 1999;10:89A.
56. McBryde KD, Kudelka TL, Kershaw, DB, Bieniewicz JC, **Mueller BA**, Giacherio DA, Smoyer WE. Clearance of Arginine for Urea Cycle Defects by Hemodialysis. *J Am Soc Neph* 2001;12:357A.
57. Kays MB, Overholser BR, **Mueller BA**, et al. Effect of sevelamer and calcium acetate on the relative oral bioavailability of ciprofloxacin. *J Am Soc Nephrol* 2002;13:257A-257A.
58. Mottes TA, Pasko DA, **Mueller BA**. Conditioning of blood prime using Prisma®-based CVVHD for pediatric patients. *Blood Purification* 2003;21:200.
59. Pasko DA, Mottes TA, **Mueller BA**. Conditioning of Blood Prime Using Diapact®-based CVVHD for Pediatric Patients. *Blood Purification* 2003;21:201.
60. Pasko DA, Churchwell MD, **Mueller BA**. Development of an In vitro Model of Continuous Renal Replacement Therapy (CRRT) Solute Removal. *Blood Purification* 2004;22:236.
61. Pasko DA, Churchwell MD, **Mueller BA**. Influence of Ultrafiltrate Production Rate on Sieving Coefficient (SC) in Continuous Venovenous Hemofiltration (CVVH). *Blood Purification* 2004;22:241.
62. Btaiche IF, Pasko DA, Nakamura AT, Jain JC, **Mueller BA**. Daily trace element losses via continuous venovenous hemofiltration using an in-vitro model. *J Parenter Enteral Nutr* 2004; 28:S6-7.

**Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

63. Pasko DA, Btaiche IF, Nakamura AT, Jain JC, **Mueller BA**. In-vitro clearance of trace elements via continuous venovenous hemofiltration. *J Parenter Enteral Nutr* 2004; 28:S7-8.
64. Pasko DA, Churchwell MD, **Mueller BA**. Duration of continuous venovenous hemodialysis and dialysate flow rate on solute saturation coefficient. 2004 European Society of Clinical Pharmacy Conference, Poster Presentation, Paris, France. April 2004.
65. Pasko DA, Churchwell MD, **Mueller BA**. Duration of continuous hemofiltration and ultrafiltration rate influence on sieving coefficients. 2004 European Society of Clinical Pharmacy Conference, Poster Presentation, Paris, France. April 2004.
66. Churchwell MD, **Mueller BA**. CVVHD Transmembrane clearance of daptomycin with two different hemodiafilters. 44th ICAAC meeting, November, 2004.
67. Churchwell MD, Pasko, DA, **Mueller BA**. CVVH Transmembrane clearance of daptomycin with two different hemodiafilters. *Pharmacotherapy*, 2004;1447 (abstract #174).
68. **Mueller BA**, Churchwell MD, Pasko DA, Smoyer W. Enhanced valproic acid dialytic clearance with an albumin-based dialysate in continuous venovenous hemodialysis. *Blood Purification* 2005;23:149-74.
69. Churchwell MD, Pasko DA, Smoyer WE, **Mueller BA**. Albumin-supplemented dialysate enhances clearance of valproic acid (VPA) during in-vitro continuous venovenous hemodialysis (CVVHD). *J Am Soc Nephrol* 2005;16:252A (Abstract# TH-PO618).
70. Churchwell MD, Pasko DA, Smoyer WE, **Mueller BA**. Albumin-supplemented dialysate enhances clearance of carbamazepine (CBZ) during in-vitro continuous venovenous hemodialysis (CVVHD). *Am Soc Nephrol* 2005;16:253A (Abstract # TH-PO619).
71. Grio M, Churchwell MD, Pasko DA, Smoyer WE, **Mueller BA**. Albumin-supplemented dialysate does not enhance clearance of phenytoin (PHT) during in-vitro continuous venovenous hemodialysis (CVVHD). *J Am Soc Nephrol* 2005;16:253A (Abstract # TH-PO620).
72. **Mueller BA**, Levy S, Lamp SC, Friedrich LV. Post marketing experience with daptomycin (DAP) in patients receiving renal replacement therapy (RRT). *J Am Soc Nephrol* 2005;16:921A:PUB640.
73. Grio MC, Churchwell MD, Seroogy JS, Barriere S, **Mueller BA**. Hydroxypropyl beta cyclodextrin transmembrane venovenous hemofiltration (CVVH). *Blood Purification* 2006;24:267.
74. Pasko DA, Btaiche IF, Jain JC, **Mueller BA**, Churchwell MD. Trace element clearance in critically ill patients treated with continuous venovenous hemodiafiltration (CVVHDF). *Blood Purification* 2006;24:268.
75. Pasko DA, Churchwell MD, Btaiche IF, Jain JC, **Mueller BA**. Trace mineral clearance in pediatric patients supported by continuous venovenous hemodiafiltration (CVVHDF). *Blood Purification* 2006;24:269.
76. J.H. Patel, M.C. Grio, M.D. Churchwell, J. Seroogy, S. Barriere, **B.A. Mueller**. Telavancin transmembrane clearance during in-vitro continuous venovenous hemofiltration (CVVH). Poster #1538. The 16th European Congress of Clinical Microbiology and Infectious Diseases. *Clinical Microbiology and Infection* 2006 (electronic version)
77. J.H. Patel, M.C. Grio, M.D. Churchwell, J. Seroogy, S. Barriere, **B.A. Mueller**. Telavancin transmembrane clearance during in-vitro continuous venovenous hemodialysis (CVVHD). Poster #1539. The 16th European Congress of Clinical Microbiology and Infectious Diseases. *Clinical Microbiology and Infection* 2006 (electronic version)
78. **Mueller B**, Levy S, Lamp K, Friedrich L, Russo R. Experience with daptomycin in patients with renal insufficiency. The 16th European Congress of Clinical Microbiology and Infectious Diseases. *Clinical Microbiology and Infection* 2006 (electronic version)

**Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

79. Vilay AM, Stevenson JM, Churchwell MD, Patel JH, De Pestel DD, Sorgel F, Kinzig-Schippers M. **Mueller BA**. Ertapenem transmembrane clearance during modeled continuous hemodialysis. *Blood Purification* 2008;26:172-3.
80. Vilay AM, Stevenson JM, Churchwell MD, Patel JH, De Pestel DD, Sorgel F, Kinzig-Schippers M. **Mueller BA**. Ertapenem transmembrane clearance during modeled continuous hemofiltration. *Blood Purification* 2008;26:173.
81. **Mueller BA**, Church BM, Bentz KM. Electrolyte control and supplementation in continuous venovenous hemodialysis (CVVHD) patients receiving a standardized dialysate. *Blood Purification* 2008;26:172.
82. Salama NN, Fleming GM, Cooke KR, **Mueller BA**. Absence of etanercept clearance in modeled continuous hemofiltration. *Blood Purification* 2008;26:183.
83. Vilay AM, Grio M, DePestel DD, Sowinski KM, Gao L, Salama NN, **Mueller BA**. Daptomycin pharmacokinetics in patients treated with continuous venovenous hemodialysis. *J Am Soc Nephrol* 2008; 19: 691A (Abstract #SA-PO2581).
84. Salama NN, Segal J, Churchwell MD, Patel JH, Gao L, Heung M, **Mueller BA**. Intradialytic administration of daptomycin in end stage renal disease patients. *J Am Soc Nephrol* 2008; 19: 737A (Abstract #SA-PO2772).
85. Salama NN, Segal J, Churchwell MD, Patel JH, Gao L, Heung M, **Mueller BA**. Daptomycin serum concentrations are maintained in a 2- and 3- day interdialytic period. *J Am Soc Nephrol* 2008; 19: 738A (Abstract #SA-PO2773).
86. Vilay AM, **Mueller BA**, Lamp KC. Experience with daptomycin for bacteremia in hemodialysis patients. *J Am Soc Nephrol* 2008; 19: 927A (Abstract #PUB517).
87. Heung M, Macnowski JP, Vilay AM, **Mueller BA**. Counting calories in the ICU: Impact of CRRT utilizing ACD-A based regional citrate anticoagulation. *JASN* 2009;20:200A.
88. Heung M, Macnowski JP, Vilay AM, **Mueller BA**. Counting calories in the ICU: Impact of CRRT utilizing ACD-A based regional citrate anticoagulation. Poster presented at 2009 ASN National Meeting, San Diego, CA. *JASN* 2009;20:200A.
89. Eyler RF, Heung M, Pleva M, Sowinski KM, Park PK, Napolitano LM, **Mueller BA**. Oseltamivir & oseltamivir carboxylate pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis (CVVHD). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy meeting, Sept 12-15, 2010 in Boston, MA. Abstract # A1-1999.
90. Eyler RF, Vilay AM, Heung M, Pleva M, Sowinski KM, Daryl DD, **Mueller BA**. Pharmacokinetics of Ertapenem in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD) or Hemodiafiltration (CVVHDF) [Abstract]. *J Am Soc Nephrol* 22, 2011: 314A.
91. A. N. Mohamed, R. F. Eyler , A. Vilay 3, M. Heung, **B. A. Mueller**, K. M. Sowinski. Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration. (CVVHD/F) American Association of Pharmaceutical Scientists, May, San Diego, CA
92. Mohamed AN, Eyler RF, Vilay AM, Heung M, **Mueller BA**, Sowinski KM. Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemofiltration. 2012 AAPS Annual Meeting and Exposition; October 14-18, 2012; Chicago, IL. Poster R6370.
93. **Mueller BA**, Eyler RF, Vilay AM, Heung M, Sowinski KM. Potential of therapeutic drug monitoring of ertapenem and daptomycin using effluent in continuous renal replacement therapy. *J Am Soc Nephrol* 2012; 23: 85A-6A. (Abstract #SA-OR088).
94. **Mueller BA**, Scoville BA, Eyler EF, Heung M, Segal JH. Pharmacokinetics of Single Dose Oral Ranolazine in Subjects Receiving Maintenance Hemodialysis. [Abstract] *J Am Soc Nephrol* 23, 2012: 559A.

## Bruce A. Mueller, PharmD, FCCP, FASN, FNKF

95. Scoville BA, Salama NN, Segal JH, Heung M, **Mueller BA**. Pharmacokinetics of a 1,000 mg Dose of Ranolazine in Subjects Receiving Maintenance Hemodialysis. Society of Critical Care Medicine Meeting 2013.
96. SJ Lewis SJ, Switaj L, **Mueller BA**. Tedizolid clearance by in vitro continuous renal replacement therapy model. Critical Care 2015, 19(Suppl 1):P113 (16 March 2015).
97. Gharibian KN, Lewis SJ, Bull JL, Pitre JJ, Scoville BA, Velenosi TJ, Urquhart BL, Perkins NC, **Mueller BA**. Effect of Computationally-Optimized Vibration on Clearance of Solutes During In Vitro Hemodialysis [Abstract]. J Am Soc Nephrol 26, 2015: 513A.
98. Gharibian KN, Lewis SJ, **Mueller BA**. Cefepime Dosing in Modeled Critically Ill Patients Receiving SHIFT Hemofiltration or Hemodialysis Renal Replacement Therapies [Abstract]. J Am Soc Nephrol 26, 2015: 745A.
99. Gharibian KN, Lewis SJ, **Mueller BA**. Identification of Optimal Ceftazidime Dosing Regimens in Modeled Critically Ill Patients Receiving SHIFT Renal Replacement Therapy [Abstract]. J Am Soc Nephrol 26, 2015: 745A.
100. Lewis SJ, Gharibian KN, **Mueller BA**. Use of Monte Carlo Simulation to Determine Optimal Meropenem Regimens in Patients Receiving SHIFT Renal Replacement Therapy [Abstract]. J Am Soc Nephrol 26, 2015: 745A.
101. Lewis SJ, Gharibian KN, **Mueller BA**. Evaluation of Piperacillin/Tazobactam Regimens in Patients with SHIFT Renal Replacement Therapy [Abstract]. J Am Soc Nephrol 26, 2015: 746A.
102. Gharibian KN, Lewis SJ, Heung M, Segal JH, Salama NN, **Mueller BA**. Telavancin pharmacokinetics in patients with chronic kidney disease receiving hemodialysis. Pharmacotherapy 2016;36(12):Abstract.
103. Gharibian KN, **Mueller BA**. Influence of hemodialyzer permeability and flow rate on the dialytic clearance of regadenoson in an in vitro hemodialysis model. Pharmacotherapy 2016;36(112):Abstract.
104. Nigwekar SU, Pai AB, **Mueller BA**, Costello GM, Dean MC, Sherman C. Impact of Hemodialysis on the Concentrations of Sodium and Potassium During Infusion of Sodium Thiosulfate Using an In Vitro Hemodialysis Model. ASN Kidney Week 2019; Abstract FR-PO443.

### VIDEOS/AUDIO

1. **Mueller BA**, Carter RA. Urinary tract infections. Two-hour videotape for the Drug Therapy Monitoring Certificate Program, Purdue University, 1990.
2. **Mueller BA**, Carter RA. Pneumonia. Two-hour videotape for the Drug Therapy Monitoring Certificate Program, Purdue University, 1991.
3. **Mueller BA**. Renal Pathophysiology Module in the Pathophysiology Curricular Resources for the American Association of Colleges of Pharmacy. Seven invited presentations - videotapes and print materials, 1991.

Unit 1	Glomerular Disease	Unit 5	Nephrolithiasis
Unit 2	Tubulointerstitial Disease (Acute Renal Failure)	Unit 6	Drug-induced Nephrotoxicity
Unit 3	Chronic Renal Failure, Part 1	Unit 7	Acid-Base Balance
Unit 4	Chronic Renal Failure, Part 2		
4. **Mueller BA**, Brown CH. Pneumonias. Two-hour videotape for the Consultant Pharmacist Certificate Program, Purdue University, 1992.
5. **Mueller BA**, Blank JW. Urinary Tract Infections. Two-hour videotape for Drug Therapy Monitoring Certificate Program. Purdue University, 1996.

## Bruce A. Mueller, PharmD, FCCP, FASN, FNKF

6. **Mueller BA**, Blank JW. Renal Failure. Two-hour videotape for Drug Therapy Monitoring Certificate Program. Purdue University, 1996.
7. **Mueller BA**. PK-PD Considerations and Dosing of Key Antibiotics in CRRT and Critical Illness. IDMED Series 2012.
8. **Mueller BA**. NephroPharmacology: Tubular talk, national podcast June 3, 2018.  
<http://www.nephjc.com/news/2018/5/26/tubular-talk>
9. **Mueller BA**. Drug dosing in the ICU. iCritical Care Podcast. Society of Critical Care Medicine. 2018.  
<https://www.sccm.org/Communications/iCritical-Care/All-Audio-iCritical-Care/SCCM-Pod-365-Medications-and-RRT-We-Know-How-to-Dose>
10. **Mueller BA**. Antibiotic dosing for PIRRT. NxStage Live Webinar, April 9, 2019
11. **Mueller BA** Continuous Renal Replacement Therapy. Pharmacy To Dose: The Critical Care Podcast. June 16, 2020 <https://pharmacytodose.com/2020/06/18/medication-dosing-in-crrt-show-notes/>

### PRESENTATIONS

- "Drug Dosing", 4th Asia Pacific AKI CRRT, Bangkok, Thailand. December 11-14,2020
- "The Role of the Pharmacist for CRRT delivery", 4th Asia Pacific AKI CRRT, Bangkok, Thailand. December 11-14, 2020
- "Challenges in AKI/ICU management", 4th Asia Pacific AKI CRRT, Bangkok, Thailand. December 11-14, 2020
- "How Do I Adjust Drugs During RRT", 4th Asia Pacific AKI CRRT, Bangkok, Thailand. December 11-14, 2020
- "Relebactam and Imipenem Clearance During Ex Vivo Continuous Renal Replacement Therapy" 29<sup>th</sup> ECCMID Conference, Amsterdams, Netherlands, April 13-16, 2019
- "Hitting the Mark: Improving Antibiotic Dosing in Patients with Altered Renal States" ASHP Midyear, Anaheim, California, December 3, 2018
- "Best Practices in Renal Dosing" AKPhA Academy of Health-System Pharmacy Fall Conference, Anchorage, Alaska, October 20, 2018
- "Continuous Renal Replacement Therapy Overview." AKPhA Academy of Health-System Pharmacy Fall Conference, Anchorage, Alaska, October 20, 2018
- "Best Practices in Renal Dosing." MAD-ID Meeting, Orlando Florida, May 11, 2018
- "Drugs to Give and Drugs to Avoid." SCCM 47<sup>th</sup> Critical Care Conference, San Antonio, Texas, February 28, 2018
- "Medications and RRT: We know how to dose, right?" SCCM 47<sup>th</sup> Critical Care Conference, San Antonio, Texas, February 27, 2018
- "Prevention and Treatment of Hypophosphatemia in Critically Ill Patients Receiving CRRT. ASHP Midyear, Orlando, Florida, December 3, 2017
- "Drug Dosing in AKI, Including Impact of RRT." ASN Kidney Week Conference, New Orleans, Louisiana, November 1, 2017
- "Influence of Cefepime Dosing Timing Relative to Daily Hemodialysis in Critically Ill Patients in Achieving Therapeutic Targets: When the Dose Is Given Is More Important Than What Dose Is Given." AKI & CRRT Conference, San Diego, California, March 8, 2017

## Bruce A. Mueller, PharmD, FCCP, FASN, FNKF

“Antibiotics and CRRT Dosing.” Spectrum Health Pharmacy Grand Rounds, Grand Rapids, Michigan, February 20, 2017

“A Comparison of 2 Different Dialysate Phosphate Supplementation Approaches for Continuous Renal Replacement Therapy” Michael Heung, Alexander Shaw, Weerachai Chaijamorn, Poster presentation, American Society of Nephrology Annual Meeting, Chicago, Illinois, November 2016.

“Pharmacokinetics of telavancin in renally impaired subjects.” Invited lecture, Theravance PK/PD Advisory Board Meeting. Charlotte, North Carolina, August 2, 2016

“Pharmacokinetics of telavancin in patients receiving hemodialysis.” Invited lecture, Theravance Medical Science Liaison Training Meeting. Charlotte, North Carolina, July 26, 2016.

“Using team-based interprofessional education to enhance student knowledge of healthcare professional roles,” Poster presentation with B. Sweet. American Association of Colleges of Pharmacy Annual Meeting, Anaheim, California. July 25, 2016.

“Decreased Antibiotic Efficacy in Renal Impairment: Are We Getting the Dose Wrong?” American Society for Microbiology (ASM) Microbe 2016. Invited platform presentation, Boston, Massachusetts. June 18, 2016.

“Drug Dosing In SHIFT Dialysis”. 2016 National Teaching Institute & Critical Care Exposition; American Associate of Critical-Care Nurses. New Orleans, Louisiana. May 17, 2016.

“Advising Model at the University of Michigan: Pharmacy Phamily.” University of Illinois Chicago College of Pharmacy Faculty Retreat, Lake Geneva, Wisconsin. May 11, 2016.

“Drug Dosing in AKI and CRRT: Know When to Hold Them.” Acute Care Nephrology Symposium, University of Cincinnati, Cincinnati, Ohio. May 6, 2016.

“Pharmacy Research as a Career Choice”, University of Michigan Undergraduate Research Opportunity Program. Ann Arbor, Michigan. March 22, 2016.

“Drug Induced Kidney Injury in the ICU: Mechanisms, Susceptibility, Diagnosis, Management Strategies”. 21st International Conference on Advances in Critical Care Nephrology. San Diego, California. February 18, 2016.

Shaw A, Lewis SJ, Chaijamorn W, **Mueller BA**. “Ciprofloxacin Dosing in Critically Ill Patients Receiving SHIFT Hemofiltration or Hemodialysis Renal Replacement Therapies”. 21st International Conference on Advances in Critical Care Nephrology. San Diego, California. Poster presentation February 17, 2016.

Chaijamorn W, Lewis SJ, Shaw AR, **Mueller BA**. Monte Carlo simulations to determine optimal levofloxacin dosing for gram negative infections in patients receiving SHIFT renal replacement therapy. (Poster presentation; Abstract No. 71) 21st International Conference on Advances in Critical Care Nephrology. San Diego, California. Poster presentation February 17, 2016.

Chaijamorn W, Lewis SJ, Shaw AR, Gharibian KN, **Mueller BA**. Monte Carlo simulations to determine optimal levofloxacin regimens for Streptococcus pneumoniae infections in patients receiving SHIFT renal replacement therapy (Poster presentation; Abstract No. 72) 21st International Conference on Advances in Critical Care Nephrology. San Diego, California. Poster presentation February 17, 2016.

“Managing Antibiotic Dosing in Patients Receiving SHIFT”. 21st International Conference on Advances in Critical Care Nephrology. San Diego, California. February 17, 2016.

“CRRT Dose/Fluid/Drug Dosing: Hands On Workshop” 21st International Conference on Advances in Critical Care Nephrology. San Diego, California. February 16, 2016.

“Evaluation of Piperacillin/Tazobactam Regimens in Patients with SHIFT Renal Replacement Therapy.” Poster presentation. Presented at American Society of Nephrology (ASN) Annual Meeting 2015, San Diego, California. November 7, 2015.

**Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

“Use of Monte Carlo Simulation to Determine Optimal Meropenem Regimens in Patients Receiving SHIFT Renal Replacement Therapy.” Poster presentation. Presented at American Society of Nephrology (ASN) Annual Meeting 2015, San Diego, California. November 7, 2015.

“Identification of Optimal Ceftazidime Dosing Regimens in Modeled Critically Ill Patients Receiving SHIFT Renal Replacement Therapy.” Poster presentation. Presented at American Society of Nephrology (ASN) Annual Meeting 2015, San Diego, California. November 7, 2015.

“Cefepime Dosing in Modeled Critically Ill Patients Receiving SHIFT Hemofiltration or Hemodialysis Renal Replacement Therapies.” Poster presentation. Presented at American Society of Nephrology (ASN) Annual Meeting 2015, San Diego, California. November 7, 2015.

“Effect of Computationally-Optimized Vibration on Clearance of Solutes During In Vitro Hemodialysis.” Poster presentation. Presented at American Society of Nephrology (ASN) Annual Meeting 2015, San Diego, California. November 6, 2015.

“Innovative Approaches to Implementing Required Research Experiences in Doctor of Pharmacy Curricula”, invited platform presentation with G Sweet, K Janke, T Stratton, S Reidt. American Association of Colleges of Pharmacy Annual Meeting, National Harbor, Maryland. July 12, 2015.

“Drug Clearances with Emerging Technologies”, invited platform presentation, American Society of Artificial Internal Organs Annual Meeting, Chicago, Illinois. June 27, 2015.

“New Approaches to Improve Patient Outcomes in Critically Ill Patients Receiving Renal Replacement Therapies”, invited presentation, Baxter Pharmaceuticals Visiting Professorship, Deerfield, Illinois. June 24, 2015.

“Breaking Down the Silos of Pharmacy Education.” 65th Annual University of Wisconsin Kremers Lecture, Madison, Wisconsin. April 21, 2015.

“Drug Dosing in AKI” Critical Care Nephrology: 2014 Update Sessions. Invited platform presentation at the American Society of Nephrology Annual Meeting, Philadelphia, Pennsylvania. November 12, 2014.

“Utility of In vitro Approaches to Help Inform Dosing” invited platform presentation at the Standardized Pharmacokinetic Assessment in Patients receiving Continuous Renal Replacement Therapy Meeting sponsored by the Kidney Health Initiative. Philadelphia, Pennsylvania. November 11, 2014.

“Anti-infective Drug Use and Intensive Care” invited Keynote Presentation at the Nephropharmacology Meeting, Ulm, Germany. October 11, 2014.

“Experiential Education in the New U of M PharmD. Curriculum”, presented at the Ohio State University College of Pharmacy, Columbus Ohio. June 17, 2014.

Pharmacy Research: Asking the Right Questions. International Continuous Renal Replacement Therapy Meeting, San Diego, California. March 6, 2014.

Drug Dosing, Pharmacokinetics, Drug Clearance, International Continuous Renal Replacement Therapy Meeting, San Diego, California. March 4, 2014.

A Pharmacist’s View of Renal Replacement Therapy in the ICU. APAKI Meeting, New York, New York. September 19, 2013.

A Pharmacist’s View of Renal Replacement Therapy in the ICU. APAKI Meeting, San Francisco, California. August 9, 2013.

A Pharmacist’s View of Renal Replacement Therapy in the ICU. APAKI Meeting, Boston, Massachusetts. June 22, 2013.

**Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

Pharmacokinetics and Pharmacodynamics of antibiotics in special populations. Ann Arbor, Michigan. August 1, 2012.

Drug Dosing in Acute Therapies. National Kidney Foundation Annual Meeting, Washington, District of Columbia. May 13, 2012.

Rethinking How We Determine Drug Removal in Patients Requiring CRRT. National Kidney Foundation Annual Meeting, Washington, District of Columbia. May 11, 2012.

Essentials for Developing, Nurturing and Growing a CRRT Program. The 17th Annual International Conference on Continuous Renal Replacement Therapies (CRRT 2011), San Diego, California. February 17, 2012.

Emerging Strategies in AKI and Extracorporeal Support. The 17th Annual International Conference on Continuous Renal Replacement Therapies (CRRT 2011), San Diego, California. February 17, 2012.

Drug Management in CRRT. The 17th Annual International Conference on Continuous Renal Replacement Therapies (CRRT 2011), San Diego, California. February 16, 2012.

Renal Replacement Therapy for AKI: Current Practice and Emerging Trends. ASN Renal Week. Philadelphia, Pennsylvania. November 10, 2011.

Considerations for empiric use of Daptomycin for SAB & cSSI. Alpena, Michigan. November 3, 2011.

Considerations for Aranesp Use in Hospitals – Nephrology Perspectives. Nephrology Associates, Tulsa, Oklahoma. October 6, 2011.

Use of Erythropoiesis Stimulating Agents in the Hospital. Oklahoma Society of Health Systems Pharmacists, Tulsa, Oklahoma. October 6, 2011.

Continuous Renal Replacement Therapy. Pharmacy Grand Rounds, Edmonton, Alberta Canada. June 7, 2011.

Drug Dosing Dilemmas in Acute Kidney Injury and CRRT and Hybrid RRT. National Kidney Foundation, Las Vegas, Nevada. April 27, 2011.

Nephrology. 2011 Updates in Therapeutics: The Ambulatory Care Preparatory Review Course, Columbus, Ohio. April 8, 2011.

PK/PD Issues in Renal Replacement Therapy. 32nd Annual Madison Clinical Conference, Middleton, Wisconsin. March 30, 2011.

HW5 Essentials for Developing, Nurturing and Growing a CRRT Program. The 16th Annual International Conference on Continuous Renal Replacement Therapies (CRRT 2011), San Diego, California. February 22, 2011.

B19 Drug Management in CRRT. The 16th Annual International Conference on Continuous Renal Replacement Therapies (CRRT 2011), San Diego, California. February 22, 2011.

Pharmacy Support. The 16th Annual International Conference on Continuous Renal Replacement Therapies (CRRT 2011), San Diego, California. February 22, 2011.

Pre-Pharmacy Student Organization Professional Panel, Ann Arbor, Michigan. November 30, 2010

Considerations for Aranesp use in Hospitals – Nephrology Perspectives, Tallahassee, Florida. November 2, 2010

Dosing in Renal Patients, Boston, Massachusetts. September 12, 2010

Consideration for Aranesp use in Hospitals- Nephrology Perspectives, Chesapeake, Virginia. September 8, 2010

Consideration for Aranesp use in Hospitals – Nephrology Perspectives, Decatur, Georgia. July 27, 2010



**Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

Considerations for Aranesp use in Hospitals – Nephrology Perspectives, Shreveport, Louisiana. June 22, 2010

Considerations for Aranesp use in Hospitals – Nephrology Perspectives, Milan, Ohio. May 19, 2010

Drug Removal by Continuous Renal Replacement Therapy (CRRT) and Hybrid Therapies. Kidney Disease: Improving Global Outcomes (KDIGO) Meeting, Baltimore, Maryland. May 14-15, 2010.

Pharmacokinetics in Patients on Continuous Renal Replacement Therapies. Making a Difference in Infectious Diseases Pharmacotherapy (MAD-ID), Lake Buena Vista, Florida. May 6-8, 2010.

Drug Dosing and the Obese Patient. Making a Difference in Infectious Diseases Pharmacotherapy (MAD-ID), Lake Buena Vista, Florida. May 6-8, 2010.

Considerations for Aranesp use in Hospitals – Nephrology Perspectives, New Bern, North Carolina. April 27, 2010

Drug Dosing for CRRT. National Kidney Foundation Meeting, Orlando, Florida. April 17, 2010

Considerations for Aranesp use in Hospitals – Nephrology Perspectives, Valdosta, Georgia. March 31, 2010

Considerations for Aranesp use in Hospitals – Nephrology Perspectives, Tifton, Georgia. March 31, 2010

Considerations for Aranesp use in Hospitals – Nephrology Perspectives, Birmingham, Michigan. March 30, 2010

Consideration for Aranesp use in Hospitals – Nephrology Perspectives, Lima, Ohio. March 23, 2010

Current Hospital Perspectives on the Use of Erythropoiesis Stimulating Agents, Dayton, Ohio. January 26, 2010

Macnowski J, **Mueller BA**, Vilay AM, Heung M. Estimating glucose caloric impact of CRRT utilizing regional citrate anticoagulation with ACD-A. International CRRT Conference, San Diego, California. Poster presented at 2009 Meeting.

Optimizing Antimicrobial Therapy During Renal Replacement Therapy: A Focus on Gram Positive Infections, Dearborn, Michigan. November 23, 2009

Current Hospital Perspectives on the Use of Erythropoiesis Stimulating Agents, Shreveport, Louisiana. November 12, 2009

Drug Dosing in AKI. American Society of Nephrology, San Diego, California. October 28, 2009

Current Hospital Perspectives on the Use of Erythropoiesis Stimulating Agents, Trenton, New Jersey. October 15, 2009

Continuous Renal Replacement Therapy. ICAAC, San Francisco, California. September 12-15, 2009

Antibiotic Dosing Principles in Patients with Acute Kidney Injury. University of Wisconsin Medical School Nephrology Grand Rounds, Madison, Wisconsin. June 23, 2009.

CRRT: Pharmacotherapy Considerations. NxStage Web Seminar. April 28, 2009.

Current Hospital Perspectives on the Use of Erythropoiesis Stimulating Agents, Corpus Christi, Texas. April 14, 2009.

Treatment of MRSA in patients with renal failure, Ann Arbor, Michigan. April 1, 2009

Current hospital perspectives on the use of erythropoiesis stimulating agents (ESAs). Aranesp® Speaker Training Webcast. March 30, 2009.

## **Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

Treatment of MRSA in patients with renal failure, Grand Rapids, Michigan. March 26, 2009.

Current Hospital Perspectives on the Use of Erythropoiesis Stimulating Agents, Birmingham, Michigan. March 25, 2009.

Fundamentals of CRRT. International Continuous Renal Replacement Meeting, San Diego, California. February 25-28, 2009.

The appropriate use of daptomycin in MRSA for cSSS's and bacteremia, including right-sided endocarditis, Birmingham, Michigan. January 21, 2009.

Current hospital perspectives on the use of erythropoiesis stimulating agents, Austin, Texas. January 14, 2009.

Antibiotic dosing considerations in CRRT. Physician Roundtable discussion, Ft. Myers, Florida. December 11, 2008.

Use of Cubicin in patients requiring renal replacement therapies, Waltham, Massachusetts. November 19, 2008.

Current Hospital Perspectives on the Use of Erythropoiesis Stimulation Agents. Southeastern Pennsylvania Society of Health-System Pharmacist meeting, York, Pennsylvania. November 11, 2008.

Drug Dosing in Acute Kidney Injury. American Society Nephrology Annual Meeting, Philadelphia, Pennsylvania. November 4-9, 2008.

Current Hospital Perspectives on the Use of Erythropoiesis Stimulation Agents, Birmingham, Michigan. October 28, 2008.

Translational research: pharmacotherapy in patients requiring renal replacement therapy. Nationwide Children's Hospital, Columbus, Ohio. October 23, 2008.

Current Hospital Perspectives on the Use of Erythropoiesis Stimulating Agents, Pinehurst, North Carolina. October 8, 2008.

Drug Therapy and Dosing in ESRD. University of Toledo College of Pharmacy. October 5, 2008.

Current Hospital Perspectives on the Use of Erythropoiesis Stimulating Agents, Lowell, Massachusetts. October 2, 2008.

Daptomycin Pharmacokinetics in Renal Replacement Therapy, Memphis, Tennessee. September 17, 2008.

Current hospital perspectives on ESA use, Dayton, Ohio. May 19, 2008

Current hospital perspectives on ESA use, Indianapolis, Indiana. May 6, 2008

Current hospital perspectives on ESA use, Toledo, Ohio. March 27, 2008

Drug Management in CRRT, CRRT 2008 Conference, San Diego, California. February 29, 2008.

Drug Management, CRRT 2008 Conference, San Diego, California. February 27, 2008.

Pharmacy Implications of Continuous Renal Replacement Therapies (CRRT), Ypsilanti, Michigan. July 20, 2007.

Association Between the Exposure to Nephrotoxic Agents with Length of Stay and Mortality in Pediatric Patients Receiving Continuous Renal Replacement Therapy, poster presentation, ASHP Midyear Conference, Las Vegas, Nevada. December 1-5, 2007.

Quantification of Pharmacy Workload in Patients Receiving Continuous Renal Replacement Therapy, poster presentation, ASHP Midyear Conference, Las Vegas, Nevada. December 1-5, 2007.

**Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

Anemia Management In Patients with CKD-2007. ASHP Midyear Conference, Las Vegas, Nevada. December 1-5, 2007.

Clinical Pearls-Intradialytic Drug Administration. ASHP Midyear Conference, Las Vegas, Nevada. December 1-5, 2007.

Nutrition Support in the ICU: Case-Based Approach. ASHP Midyear Conference, Las Vegas, Nevada. December 1-5, 2007.

Current Hospitals Perspectives on the Use of ESA's, AMGEN, Dearborn, Michigan. November 28, 2007.

Drug Dosing in AKI, American Society of Nephrology Renal Week 2007, San Francisco, California. November 1, 2007.

Current Hospital Perspectives on the Use of Erythropoiesis Stimulating Agents, AMGEN, webcast. October 15, 2007.

HD VS. HDF VS. H, CRRT Midwest Symposium, Indianapolis, Indiana. September 20-21, 2007.

Drug Dosing. CRRT Midwest Symposium, Indianapolis, Indiana. September 20-21, 2007.

Patient Safety. CRRT Midwest Symposium, Indianapolis, Indiana. September 20-21, 2007.

Update: IRB Protocol 1467 Intradialytic Daptomycin Administration and Protein Binding Determination in Chronic Hemodialysis Patients. University of Michigan Health System General Clinical Research Center, Ann Arbor, Michigan. September 12, 2007.

Pharmacy Implications of Continuous Renal Replacement Therapies (CRRT). Aurora St. Luke's Medical Center Grand Rounds, Milwaukee, Wisconsin. April 24, 2007.

Review of Pharmacokinetics in CKD, HD, PD & CRRT Patients. National Kidney Foundation Spring Clinical Meeting, Orlando, FL. April 10-14, 2007.

Drug Management. Twelfth Annual International Conference on Continuous Renal Replacement Therapies (CRRT 2006), San Diego, CA. March 8-10, 2007.

Nutritional Assessment and Support. Twelfth Annual International Conference on Continuous Renal Replacement Therapies (CRRT 2006), San Diego, CA. March 8-10, 2007.

Applying Pharmacodynamic Principles to CRRT Patients. Twelfth Annual International Conference on Continuous Renal Replacement Therapies (CRRT 2006), San Diego, CA. March 8-10, 2007.

Practical approach to pharmacokinetics in CKD. 9th International Conference on Dialysis, Advances in CKD, Austin, Texas. January 25, 2007

Overview of Drug Dosing in Continuous Renal Replacement Therapies (CRRT). Grand Rounds, Jacobi Medical Center, Bronx, NY. January 16, 2007.

Renal Anemia Continuing Education, Industry Expert Panel. Roche Laboratories, Grapevine, TX. December 12, 2006.

Modifying CRRT Dialysate: The UM Experience. Renal Replacement Therapy Kinetics Study Group, University of Michigan Health Systems. December 8, 2006.

Electrolyte and metabolic control in continuous venovenous hemodialysis (CVVHD) patients receiving a standard dialysate solution, poster presentation, ASHP Midyear Clinical Meeting, Anaheim, CA. December 4, 2006.

## **Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

Pharmacy Update for CKD and Transplant Patients. Rehabilitation Information Support Empowerment (R.I.S.E.). National Kidney Foundation of Michigan, Ann Arbor, MI. November 8, 2006.

Pharmacy Update for CKD and Transplant Patients. Rehabilitation Information Support Empowerment (R.I.S.E.). National Kidney Foundation of Michigan, Detroit, MI. October 5, 2006.

What are the Differences Between Hemodialysis/Hemofiltration? Midwest CRRT Symposium, Indianapolis, IN. September 21, 2006.

Overview of Drug Dosing in Continuous Renal Replacement Therapies. Midwest CRRT Symposium, Indianapolis, IN. September 21, 2006.

CRRT Systems and Patient Safety. Midwest CRRT Symposium, Indianapolis, IN. September 21, 2006.

Pharmacy Update for CKD and Transplant Patients. Rehabilitation Information Support Empowerment (R.I.S.E.). National Kidney Foundation of Michigan, Detroit, MI. May 10, 2006.

Telavancin Transmembrane Clearance During In Vitro Continuous Venovenous Hemofiltration. 16th European Congress of Clinical Microbiology and Infectious Diseases, Nice, France. April 4, 2006.

Telavancin Pharmacokinetics During In Vitro Continuous Venovenous Haemodialysis. 16th European Congress of Clinical Microbiology and Infectious Diseases, Nice, France. April 4, 2006.

Experience with Daptomycin in Patients with Renal Insufficiency. 16th European Congress of Clinical Microbiology and Infectious Diseases, Nice, France. April 4, 2006.

Pharmacy Update for CKD and Transplant Patients. Rehabilitation Information Support Empowerment (R.I.S.E.). National Kidney Foundation of Michigan, Detroit, MI. March 9, 2006.

Drug Management I. Eleventh Annual International Conference on Continuous Renal Replacement Therapies (CRRT 2006), San Diego, CA. March 2-4, 2006.

Nutritional Assessment and Support I. Eleventh Annual International Conference on Continuous Renal Replacement Therapies (CRRT 2006), San Diego, CA. March 2-4, 2006.

Drug Management II. Eleventh Annual International Conference on Continuous Renal Replacement Therapies (CRRT 2006), San Diego, CA. March 2-4, 2006.

Critical Care Pharmacology: What's New? Eleventh Annual International Conference on Continuous Renal Replacement Therapies (CRRT 2006), San Diego, CA. March 2-4, 2006.

Nutritional Assessment and Support II. Eleventh Annual International Conference on Continuous Renal Replacement Therapies (CRRT 2006), San Diego, CA. March 2-4, 2006.

Drug Dosing in Acute Renal Failure. The American Society of Nephrology Annual Meeting, Philadelphia, PA. November 9, 2005.

Drugs in Patients with Kidney Disease. Rehabilitation Information Support Empowerment (R.I.S.E.). National Kidney Foundation of Michigan, Ann Arbor, MI. November 7, 2005.

Effects of Therapeutic Interchange on CKD Patients, Detroit, Michigan. June 6, 2005

CRRT Dialysate and Associated Pharmacy Issues. Baxter CRRT Team. March 15-17, 2005.

Improving CRRT Patient Safety. Tenth Annual International Conference on Continuous Renal Replacement Therapies (CRRT 2005). March 10, 2005.

**Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

Pharmacotherapeutic Challenges in CRRT. Tenth Annual International Conference on Continuous Renal Replacement Therapies (CRRT 2005). March 11, 2005.

Drug Dosing in CRRT. Tenth Annual International Conference on Continuous Renal Replacement Therapies (CRRT 2005). March 12, 2005.

Continuous Renal Replacement Therapy. American Society of Health-System Pharmacists Midyear Clinical Meeting. December 6, 2004.

Drugs in Patients with Kidney Disease. Rehabilitation Information Support Empowerment (R.I.S.E.). National Kidney Foundation of Michigan. November 11, 2004.

End of the Line: Issues with Dialysis. American College of Clinical Pharmacy. October 27, 2004.

Chronic Kidney Disease: Filtering the Facts. American College of Clinical Pharmacy. October 26, 2004.

Renal Failure in Pediatrics. American College of Clinical Pharmacy. October 26, 2004.

Chronic Kidney Disease: Filtering the Facts. American College of Clinical Pharmacy. October 25, 2004.

Drugs in Pediatrics. Midwest CRRT Meeting, Indianapolis, Indiana. October 1, 2004.

Writing the prescription, or Nursing Management or Show and Tell. Midwest CRRT Meeting, Indianapolis, Indiana. October 1, 2004.

Drug Dosing. Midwest CRRT Meeting, Indianapolis, Indiana. September 29, 2004.

Implication of New Types of Renal Replacement Therapy for Pediatric Patients. Food and Drug Administration, Bethesda, Maryland. August 9-10, 2004.

In vitro Modeling of New Types of Renal Replacement Therapies (RRT). Food and Drug Administration, Bethesda, Maryland. August 9-10, 2004.

Conversion from erythropoietin to darbepoietin. Richmond County Pharmacists Association, Augusta, GA. June 15, 2004.

Conversion from erythropoietin to darbepoietin. Indiana University Medical Center, Indianapolis, IN. May 27, 2004.

Comparison of Diffusive and Convective Clearance with AN69 and Polysulfone Hemodiafilters in CVVH and CVVHD. 2004 Continuous Renal Replacement Therapy Conference, Poster Presentation, San Diego, CA. February 2004.

Development of an In vitro Model of Continuous Renal Replacement Therapy (CRRT) Solute Removal. 2004 Continuous Renal Replacement Therapy Conference, Poster Presentation, San Diego, CA. February 2004.

Influence of Ultrafiltrate Production Rate on Sieving Coefficient (SC) in Continuous Venovenous Hemofiltration (CVVH). 2004 Continuous Renal Replacement Therapy Conference, Poster Presentation, San Diego, CA. February 2004.

Duration of Continuous Venovenous Hemodialysis and Dialysate Flow Rate on Solute Saturation Coefficient. 2004

European Society of Clinical Pharmacy Conference, Poster Presentation, Paris, France. April 2004.

Duration of Continuous Hemofiltration and Ultrafiltration Rate Influence on Sieving Coefficients. 2004 European Society of Clinical Pharmacy Conference, Poster Presentation, Paris, France. April 2004.

**Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

Continuous Renal Replacement Therapy. Presented at The 8th Annual Infectious Diseases and Critical Care Symposium, Detroit Medical Center, Dearborn, Michigan. January 30, 2004.

Drug Dosing in Continuous Renal Replacement Therapies. Richmond, VA. October 9, 2003.

Drug Dosing in CRRT. Presented at Indiana University and Clarian Midwest CRRT Symposium, Indianapolis, Indiana. October 2, 2003.

Obtaining Adequate Clearances in the ICU, presented at Indiana University and Clarian Midwest CRRT Symposium, Indianapolis, Indiana. October 3, 2003.

Chronic Kidney Disease: Filtering the Facts. American College of Clinical Pharmacy. October 25, 2004.

University of Michigan Inpatient Conversion to Darbepoietin. Medical and Nursing in-service. September 9-12, 2003.

Considerations of Continuous Renal Replacement Therapies (CRRT). Presented at Michigan Pharmacists Association's Annual Convention, Dearborn, Michigan. February 22, 2003.

Nephrology Grand Rounds. Drug Dosing in Continuous Renal Replacement Therapies (CRRT) at the University of Michigan Medical Center, Ann Arbor, Michigan. February 5, 2003.

Considerations for starting a CRRT program, Muncie, Indiana. April 24, 2002.

A Primer on Dialysis Techniques for the Pharmacy Department. Presented at the University of Michigan Health Systems' Department of Pharmacy Services and College of Pharmacy. A Continuing Education Program for Pharmacy Technicians, Pharmacists and Other Health Care Professionals. March 14, 2002.

Practicing Renal Pharmacy, invited presentation to the NE Georgia District of the Georgia Society of Health System Pharmacists meeting, Athens, Georgia. June 19, 2001.

Becoming a Renal Pharmacist. Invited presentation at the Gateway College of Clinical Pharmacy meeting, St. Louis, Missouri. March 13, 2001.

Renal Replacement Therapies. Guest lecturer for the Doctor of Pharmacy Therapeutics course, St. Louis College of Pharmacy, St. Louis, Missouri. March 13, 2001.

Continuous Renal Replacement Therapies: Drug Dosing in Continuous Renal Replacement Therapy. Invited platform presentation at the Society of Critical Care Medicine 30th International Educational and Scientific Symposium, San Francisco, California. February 14, 2001.

Food Drug Interactions. Invited presentation to the Renal Care Group, Inc. Annual Medical Meeting, Scottsdale, Arizona. May 6, 2000.

Becoming a Renal Pharmacist. Invited presentation to pharmacists from the Carolinas Health System. Charlotte, North Carolina. March 22, 2000.

Pharmaceutical Aspects of Dialysis Technology Advances. Presented to the Nephrology Division, University of Cincinnati, Cincinnati, Ohio. March 3, 2000.

Impact of New Dialysis Technology. Presented to the College of Pharmacy, University of Michigan, Ann Arbor, Michigan. December 17, 1999.

Clinical Pharmacy Skills Demonstrator. Presented at the Alliance for Pharmaceutical Care exhibit, The National Conference of State Legislators convention, Indianapolis, Indiana. July 26, 1999.

Advances in Dialysis. Invited presentation at The Washington DC Maryland Society of Health-Systems Pharmacists, Bethesda, Maryland. June 10, 1999.

## **Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

Pharmacy Implications Arising from Advances in Dialysis. Invited presentation at the Gateway College of Clinical Pharmacy meeting, St. Louis, Missouri. March 9, 1999.

Renal Replacement Therapies. Guest lecturer for the therapeutics course, St. Louis College of Pharmacy, St. Louis, Missouri. March 8, 1999.

Pharmaceutical Implications of the PRISMA CVVH Machine. Invited presentation to pharmacists, residents and students at Methodist Hospital, Indianapolis, Indiana. March 3, 1999.

Starting a CVVH Dosing Service. Presented to St. Vincent's Hospital clinical pharmacists and pharmacy residents, Indianapolis, Indiana. February 22, 1999.

An AUC Approach for Estimating Cumulative Clearance Loss of High-Flux Hemodialyzers Reprocessed Fifteen Times with Peracetic and Acid-Hydrogen Peroxide. Poster presentation, Annual meeting of the American College of Clinical Pharmacy meeting, Cincinnati, Ohio. November, 1998.

Effect of PAHP (Peracetic Acid-Hydrogen Peroxide) Dialyzer Reuse on Drug and Solute Removal. Poster presentation, Annual meeting of the American College of Clinical Pharmacy, Cincinnati, Ohio. November, 1998.

Comparison of Fluorescence Polarization Immunoassays and Enzyme Multiplied Immunoassay Technique (EMIT) Assay for the Determination of Vancomycin Continuous Venovenous Hemofiltration. Poster presentation, Annual meeting of the American College of Clinical Pharmacy meeting, Cincinnati, Ohio. November, 1998.

Pharmaceutical Implications of Advances in Dialysis Technology invited platform presentation, Maryland Society of Health Systems Pharmacy Annual Meeting, Deep Creek Lake, Maryland. October 17, 1998.

Impact of New Dialysis Technology, invited presentation, University of Texas Health Science Center in San Antonio, San Antonio, Texas. June 12, 1998.

New Drug Update, invited platform presentation, Tri-State Renal Network, Chicago, Illinois. May 22, 1998.

The ABCs of CRRT, presented at St. Joseph's Hospital, Syracuse, New York. May 7, 1998.

Maximizing Erythropoietin Outcomes, invited platform presentation, National Kidney Foundation of IL, Annual Meeting, Chicago, Illinois. May 1, 1998.

Drug Dosing in Patients Receiving Continuous Renal Replacement Therapies, presented to New York State Chapter of ACCP, Syracuse, New York. May 8, 1998.

Effect of Changes in Dialytic Frequency, Duration and Flow Rates on Solute Kinetics and Effectiveness Clearances, poster presentation at the 1998 ACCP Spring Practice and Research Forum, June 7, 1998. Palm Springs, California.

The Effects of Bleach Reprocessing on Solute and Water Permeability of High-flux Hemodialyzers, poster presentation at the 1998 ACCP Spring Practice and Research Forum, June 7, 1998. Palm Springs, California.

Intermittent Dosing of Intraperitoneally Administered Drugs, 18th Annual Conference on Peritoneal Dialysis. Invited platform presentation, Nashville, Tennessee. February 24, 1998.

Pharmacokinetics of Automated Peritoneal Dialysis Systems, 18th Annual Conference on Peritoneal Dialysis. Invited platform presentation, Nashville, Tennessee. February 24, 1998.

Nutrition, Erythropoietin and the Dieticians, invited platform presentation at the Indiana Renal Dieticians Annual Meeting, Carmel, Indiana. November 18, 1997.

Vancomycin Assay Performance in Patients with End-Stage Renal Disease Receiving Hemodialysis With High-Flux Cellulose Triacetate Dialyzer, poster presentation, 1997 ACCP Annual Meeting, Phoenix, Arizona. November 13, 1997.

**Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

Effect of Gender on Relative Oral Bioavailability of Ciprofloxacin and Ofloxacin When Administered with an Enteral Feeding Product, poster presentation, 1997 ACCP Annual Meeting, Phoenix, Arizona. November 12, 1997.

Pharmaceutical Aspects of Hemodialysis Advances, presented to the Wisconsin Society of Hospital Pharmacists, Milwaukee, Wisconsin. September 25, 1997.

Dosing Implications of Automated Peritoneal Dialysis, presented at the Nephrology Fellow Conference, Indianapolis, Indiana. September 15, 1997.

Pharmacy Implications of the New Hemodialysis Unit at Wishard Hospital, presented to Wishard Memorial Hospital Pharmacy Department, Indianapolis, Indiana. June 29, 1997.

Drug Management in Continuous Renal Replacement Therapies, second International Conference on Continuous Renal Replacement Therapies (invited platform), February 9 & 11, 1997. San Diego, California.

Cephalosporin Pharmacokinetics in Peritoneal Dialysis, Renal Grand Rounds, Indiana University Medical Center. August 22, 1996.

Renal Replacement Therapies in the ICU: Focus on Hemofiltration, invited platform presentation. American College of Clinical Pharmacy Annual Meeting, Nashville, Tennessee. August 7, 1996.

Intradialytic Vancomycin Administration: Dialysis Membrane Effects, scientific poster presentation at American College of Clinical Pharmacy Annual Meeting, Nashville, Tennessee. August 6, 1996.

Nephrology, section leader for the Pharmacotherapy Board Certification Preparation Course, American College of Clinical Pharmacy Annual Meeting, Nashville, Tennessee. August 2 and 3, 1996.

Nephrology, section leader for the Pharmacotherapy Board Certification Preparation Course, Dallas, Texas. June 29 and 30, 1996.

Continuous Renal Replacement Therapies, invited presentation to faculty and residents from the School of Pharmacy, University of Kentucky, Lexington, Kentucky. May 29, 1996.

Pharmacologic Aspects of End Stage Renal Disease, invited platform presentation, Tri State Renal Network Meeting, Columbus, Ohio. May 10, 1996.

Falsely-Elevated Vancomycin Serum Concentrations in Patients Receiving Conventional Hemodialysis, poster presentation 1995 ASHP Midyear Clinical Meeting, Las Vegas, Nevada. December 6, 1995.

Anti-Ulcer Drug Therapy, presented at Indiana University Medical School, Family Medicine Grand Rounds. September 28, 1995.

Conundrums Faced by Physicians on the Nephrology Service, presented at the Indiana University Medical Center Nephrology Grand Rounds. September 14, 1995.

Clinical Considerations in Continuous Hemofiltration, presented at Indiana University Renal Clinical Conference in Indianapolis, Indiana. August 18, 1995.

Drug Dosing and Patient Outcome in Critically Ill Patients with Acute Renal Failure, invited presentation for Illinois College of Clinical Pharmacy, Chicago, IL. March 9, 1995.

Oral Candidiasis and Mucocutaneous Herpes Simplex Virus Prophylaxis and Treatment Practices in Oncology and Bone Marrow Transplant Patients: National Mucositis Survey Results, poster presentation at the 1995 ACCP Winter Practice and Research Forum in Orlando, Florida. February 14, 1995.



**Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

Use of Compounded Mouthwash Mixtures and Mouthcare Products in Mucositis Prophylaxis and Treatment: National Survey Results, Poster presentation at the 1995 ACCP Winter Practice and Research Forum in Orlando, Florida. February, 14, 1995.

Nephrology, section leader for the Pharmacotherapy Board Certification Preparation course given at the 1995 ACCP Winter Practice and Research Forum at Orlando, Florida. February 10 and 11, 1995.

Factors Affecting Drug Dosing in Patients with Acute Renal Failure, presented at the American Society of Hospital Pharmacists Midyear Clinical Meeting, Miami, Florida. December 7, 1994.

Drug Elimination in Acute Renal Failure, Indiana College of Clinical Pharmacy meeting, West Lafayette, Indiana. November 3, 1994.

Are Pharmacist-Specific Outcomes Really Measurable?, invited presentation, ACCP Annual Meeting, St. Louis, Missouri. August 2, 1994.

Dosing in Patients with Kidney Disease, presented to first year nephrology fellows, Indiana University Medical Center. July 8, 1994.

CVVH, presented at the Tri-State Renal Network Annual Meeting, Indianapolis, Indiana. May 13, 1994.

Pharmacokinetics in Patients with Renal Disease, presented at the Indiana Society of Hospital Pharmacists Meeting, Fort Wayne, Indiana. May 6, 1994.

Peptic Ulcer Disease: Have We Been Wrong All these Years?, presented at the Purdue Pharmacy Alumni Seminar, Indianapolis, Indiana. June 26, 1994.

Evaluating Students in the Clinical Setting, moderator at the 1994 ACCP Winter Research and Practice Forum, San Diego, California. February 8, 1994.

Effect of Enteral Feeding with Ensure on the Oral Bioavailability of Ofloxacin and Ciprofloxacin, poster presentation, 1994 ACCP Winter Forum, San Diego. California. February 8, 1994.

Impact of Enteral Feeding on Fluoroquinolone Antibiotics, at The Role of Quinolones in Hospital Pharmacy Symposia, Atlanta, Georgia. December 7, 1993.

CVVH Drug Dosing Basics, presented to Wishard Memorial Hospital pharmacists, Wishard Memorial Hospital, Indianapolis, Indiana. October 13, 1993.

Imipenem Disposition in Renal Failure, presented at the Third Annual Stuart Kleit Nephrology Symposium, Indianapolis, IN. October 10, 1993.

Pharmacokinetics in Continuous Hemofiltration, presented to nurses, physicians and pharmacists, Renal Conference, Indianapolis, IN. September 21, 1993.

Pharmacokinetic Differences Between Acute and Chronic Renal Failure, presented at Graduate Seminar, Purdue University, West Lafayette, IN. September 17, 1993.

AIDS Pharmacotherapy Update, presented to Indiana Pharmacists Association, Indianapolis, IN. September 17, 1993.

Continuous Hemofiltration Basics For The Dialysis Nurse, presented to the Am. Nephrol. Nurses Assoc., Indiana Chapter and National Association of Nephrology Technicians, Indianapolis, IN. August 29, 1993.

Pharmacokinetics in Patients with Renal Failure, presented to Indiana University nephrology fellows, Indiana University Medical Center, Indianapolis, IN. July 7, 1993.

**Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

Pharmacology Update, an invited eight hour continuing education platform program for nurses, Phoenix, AZ. May 21, 1993.

Pharmacology Update, an invited eight hour continuing education platform program for nurses, Tucson, AZ. May 20, 1993.

Management of Refractory Septic Shock with Continuous Venovenous Hemofiltration (CVVH), poster presentation at the American Society of Artificial Internal Organs Annual Meeting, New Orleans, LA. June 1993.

Comparison of Metabolic Control Achieved by Intermittent Versus Continuous Renal Replacement Therapy in Patients with Renal Failure, poster presentation at the American Society of Artificial Internal Organs Annual Meeting, New Orleans, LA. June, 1993.

Drug Dosing in Patients Receiving Continuous Hemofiltration, invited presentation American College of Clinical Pharmacy Winter Practice and Research Forum, Ft. Lauderdale, FL. February 8, 1993.

Implementation of a Residency Seminar Series: Contemporary Topics in Pharmacy, poster presentation at the American Society of Hospital Pharmacists Midyear Clinical Meeting, Orlando, FL. December 9, 1992.

Lack of Late Dissociation of Digoxin Fab Fragment Complex in a Patient with Chronic Renal Failure, poster presentation at the American Society of Hospital Pharmacists Midyear Clinical Meeting, Orlando, FL. December 8, 1992.

AIDS, Tuberculosis, and Peptic Ulcer Disease Pharmacology Update, continuing education, to registered nurses, Madison, WI. December 2, 1992.

AIDS, Tuberculosis, and Peptic Ulcer Disease Pharmacology Update, continuing education, given to registered nurses, Brookfield, WI. December 1, 1992.

Anti-retroviral Therapies, continuing education to the Central Indiana Osco pharmacists, Indianapolis, IN. October 21-22, 1992.

AIDS, Tuberculosis, and Peptic Ulcer Disease Pharmacology Update, continuing education to Indiana Nurses, Indianapolis, IN. October 2, 1992.

Extracorporeal Drug Removal, roundtable leader at the American College of Clinical Pharmacy Annual Meeting, Toronto, Canada. August 11, 1992.

Membership Practices of Professional Medical, Dental, and Pharmaceutical Organizations, platform presentation at the ACCP Annual Meeting, Toronto, Canada. August 9, 1992.

What Should be the Membership Philosophy of ACCP?, ACCP Town Meeting Moderator at the American College of Clinical Pharmacy Annual Meeting, Toronto, Canada. August 9, 1992.

Practical Guide to Common Anemias, presented at Midwest Regional Conference for Consultant Pharmacists, Indianapolis, IN. August 1, 1992.

Iron Supplementation in Dialysis Patients, presented to American Nephrology Nurses Association Local Chapter, Indianapolis, IN. July 28, 1992.

The Pharmacokinetics of Drugs in Acute Renal Failure. Do the Textbooks Need to be Rewritten?, presented at Clinical Pharmacology Conference, Wishard Memorial Hospital, Indianapolis, IN. February 25, 1992.

Drug Dosing in the First 24 Hours of CVVH When No One is Available to Help!, presented to the Indiana University Medical Center Pharmacy Department, Indianapolis, IN. Jan 20, & Feb 12, 1992.

Establishment of a Continuous Venovenous Hemofiltration (CVVH) Drug Dosing Service, poster presentation at the American Society of Hospital Pharmacists Midyear Clinical Meeting, New Orleans, LA. December 12, 1991.

## **Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

Toxic Self-Treatment of Intractable Uremic Pruritus, student poster presentation at the American Society of Hospital Pharmacists Midyear Clinical Meeting, New Orleans, LA. December 11, 1991.

Drug Dosing in Acute Renal Failure Patients Receiving Continuous Hemofiltration, presented to the Indiana College of Clinical Pharmacy, Indianapolis, IN. November 7, 1991.

Iron Replacement Strategies in Dialysis Patients Receiving Erythropoietin, presented to the Indiana Society of Hospital Pharmacists, Region 1, Indianapolis, IN. September 19, 1991.

Imipenem Pharmacokinetics in Patients with Acute Renal Failure Receiving Continuous Venovenous Hemofiltration (CVVH), platform presentation at the American College of Clinical Pharmacy Twelfth Annual Meeting, Minneapolis, MN. August 21, 1991.

Preservation of the Non-renal Clearance of Vancomycin in Patients with Acute Renal Failure (ARF) Treated with Continuous Venovenous Hemofiltration (CVVH), platform presentation at the American College of Clinical Pharmacy Twelfth Meeting, Minneapolis, MN. August 21, 1991.

CVVH and the Central Pharmacist: Manufacturing of Replacement Solutions and Rationale for Their Use, presented to the pharmacy staff of Indiana University Hospitals, Indianapolis, IN. June 17, 1991.

Drug Dosing in CVVH, presented to Pharmacy Staff at Wishard Memorial Hospital, Indianapolis, IN. March 27, 1991.

Pharmacokinetics and Endoscopic Effects of Oral Versus Buccal Piroxicam, poster presentation at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, San Antonio, TX. March 14, 1991.

The Use of Sieving Coefficients in Drug Dosing, presented at Clinical Pharmacology Noon Conference, Wishard Hospital, Indianapolis, IN. October 23, 1990.

Commonly Used Drugs in the Dialysis Unit, presented to Indiana University Hospital dialysis nurses, Indiana University Hospital. July 19, 1990.

Treatment of the Anemia of Chronic Renal Failure, presented to New Jersey Society of Hospital Pharmacists, Mount Laurel, NJ. June 8, 1990.

Update on the Treatment of AIDS, presented at the Sixth Annual Pharmacy Alumni Seminar, Purdue University. March 31, 1990.

Clinical Impact from the Provision of Educational Services by a Hospital Pharmacy Department: A Management Case Study, presented at the Twenty-fourth Annual American Society of Hospital Pharmacists Midyear Clinical Meeting, Atlanta, GA. December 1989.

Evidence for Ciprofloxacin Penetration into Human Breast Milk, poster presentation at the Twenty-fourth Annual American Society of Hospital Pharmacists Midyear Clinical Meeting, Atlanta, GA. December 1989.

Are There Any Clinical Applications for Fish Oils?, presented to the Indiana Society of Hospital Pharmacists, Region 1, Indianapolis, IN. November 16, 1989.

Bleeding Time Effects of Aspirin in Subjects Ingesting an Omega-3 Fatty Acid Enriched Diet, platform presentation at XVI World Congress on Diseases of the Chest. 55th Annual Scientific Assembly, Boston, MA. November 1, 1989.

Bleeding Time Effects of Concurrent Administration of Aspirin and Fish Oil, presented at Clinical Pharmacology Seminars, Wishard Hospital, Indianapolis, IN. September 19, 1989.

Economic Contributions of Clinical Pharmacists, presented at Seminars in Clinical Pharmacy, Methodist Hospital, Indianapolis, Indiana. February 2, 1989.

## Bruce A. Mueller, PharmD, FCCP, FASN, FNKF

Digitoxin-like Immunoreactive Substance in Adults with Renal Insufficiency, platform presentation at the American College of Clinical Pharmacy, Ninth Annual Meeting, Philadelphia, PA. July 26, 1988.

The Use of Antidepressants in Pain, resident rounds presented to clinical pharmacy faculty and students, The University of Texas Health Science Center at San Antonio and by interactive television to The University of Texas at Austin. December 1986.

### REFeree

2015	Reviewer, Drugs in R & D
2012-Present	Reviewer, Advances in Chronic Kidney Disease
2011-Present	Reviewer, Antimicrobial Agents and Chemotherapy
2011-Present	Reviewer, BioMedCentral Nephrology
2011-2012	Reviewer, Blood Purification
1998-Present	American Journal of Kidney Disease
2000-Present	Reviewer, American Journal of Health Systems Pharmacists
1994-Present	Pharmacotherapy (Editorial Panel)
1988-Present	American Journal of Health-Systems Pharmacy
1993-Present	The Annals of Pharmacotherapy (also formerly on Editorial Panel)
2008- Present	Reviewer, Critical Care Medicine
2010	Reviewer, American Journal of Cardiology
2009	Reviewer, Clinical Nutrition
2007	Reviewer, Pharmacotherapy Self-Assessment Program
2006-2013	Reviewer, Journal of Antimicrobial Chemotherapy
2006	Reviewer, Pharmacotherapy Self-Assessment Program VI
2005	Reviewer, Continuing Education Reviewers Committee, Michigan Pharmacists Association
2005	Reviewer, Journal of Antimicrobial Chemotherapy
2005	Reviewer, Hemodialysis International Journal
2005	Reviewer, American Journal of Pharmaceutical Education
2005	Reviewer, Journal of Pharmacy Technology
2005	Abstract Reviewer, 2005 Spring Practice and Research Forum of the American College of Clinical Pharmacy
2004-2005	Abstract Reviewers, Nutrition in Clinical Practice
2004	Abstract Reviewer, 2004 Annual Meeting of the American College of Clinical Pharmacy
July 2004	Reviewer, RAC Residency Research Projects
May 2003	Abstract Reviewer, 2003 Annual Meeting of the American College of Clinical Pharmacy
July 2002	Abstract Reviewer, 2002 Annual Meeting of the American College of Clinical Pharmacy

**Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

April 2002	Reviewer, University of Michigan Office of the Vice President of Research Faculty Grants and Awards program
2001	Abstract Reviewer, 2001 American College of Clinical Pharmacy Spring Practice and Research Forum
2000	Lancet
1999	Abstract Reviewer, International Congress on Clinical Pharmacy
1998	Abstract Reviewer, 1998 American College of Clinical Pharmacy Spring Practice and Research Forum
1998	Abstract Reviewer, American College of Pharmacy 1998 Annual Meeting
1998	Intensive Care Medicine
1998	Journal of Applied Therapeutics
1998	Clinical Drug Investigation Journal
1997	Abstract Reviewer, American College of Clinical Pharmacy 1997 Annual Meeting
1997	Reviewer, American Society of Hospital Pharmacists Supplemental Standard and Learning Objectives for Residency Training in Internal Medicine Pharmacy Practice.
1996	Abstract Reviewer, 1996 American College of Clinical Pharmacy Winter Practice and Research Forum
1995	Reviewer, Pharmacotherapy Self-Assessment Program II, Nephrology Module
1988-1993	Clinical Pharmacy
1990	New England Journal of Medicine

## Bruce A. Mueller, PharmD, FCCP, FASN, FNKF

### TEACHING EXPERIENCE

2014-Present	Lecturer, Opportunities in Pharmacy Lecturer, Critical Care Pharmacotherapy Lecturer, Therapeutics Lecturer, Seminar Mentor, Residents' Lecture Series Lecturer, MCRiT Summer Practicum
2012-13	Lecturer, Pharmacy 550, Opportunities in Pharmacy Lecturer, Pharmacy 567 Critical Care Pharmacotherapy Lecturer, Pharmacy 432, Therapeutics Lecturer, Pharmacy 680, Seminar Residents' Lecture Series MCRiT Summer Practicum
2010-11	MCRiT Summer Practicum Summer Science Academy, Pharmacy as a Career Choice, 11th and 12 Graders, University of Michigan Medical School Lecturer, Pharmacy 680, Seminar Lecturer, Pharmacy 550 Lecturer, Pharmacy 567 Lecturer, Pharmacy 432 Residents' Lecture Series
2009	Lecturer, Pharmacy 431, Pathophysiology and Therapeutic I Lecturer, Pharmacy 550, Opportunities in Pharmacy Lecturer, Med Chem 409, Drug Assay Lecturer, 680, Pharmacy Student Seminar Lecturer, Pharmacy 680, Seminar Lecturer 567, Introduction to Critical Care Pharmacotherapy Summer Science Academy, Pharmacy as a Career Choice, 11th and 12 Graders, University of Michigan Medical School MCRiT Summer Practicum
2008	Residents' Teaching Discussion Series, Writing Appropriate Test Questions. Lecturer, Med Chem 409, Drug Assay Summer Science Academy, Pharmacy as a Career Choice, 11th and 12 Graders, University of Michigan Medical School
2007	Lecturer, Pharmacy 680, Pharmacy Student Seminar Lecturer, Med Chem 409, Drug Assay Summer Science Academy, Pharmacy as a Career Choice, 11th and 12 Graders, University of Michigan Medical School Lecturer, Pharmacy 431, Pathophysiology and Therapeutics I Lecturer, Education 882, Introduction to Medical and Professional Education
2006	Clinical Research Lecture Series, Michigan Clinical Researchers in Training (MCRiT) Program, Sponsored by the National Institutes of Health Lecturer, Med Chem 409, Drug Assay Lecturer, Honors 291, Intro-Research

## Bruce A. Mueller, PharmD, FCCP, FASN, FNKF

2005	Summer Science Academy, Pharmacy as a Career Choice, 11th and 12 Graders, University of Michigan Medical School Course Coordinator, P510 Pharmaceutical Care III: Pharmacy Practice Preceptor for Experiential Training, Nephrology Lecturer, Med Chem 409, Drug Assay Lecturer, P550, Career Development
2004	Summer Science Academy, Pharmacy as a Career Choice, 11th and 12 Graders, University of Michigan Medical School Course Coordinator, P510 Pharmaceutical Care III: Pharmacy Practice Preceptor for Experiential Training, Nephrology Lecturer, Med Chem 409, Drug Assay Lecturer, P550, Career Development
2003	Course Coordinator, P510, Pharmaceutical Care III: Pharmacy Practice Preceptor for Experiential Training, Nephrology
2002	Lecturer, Med Chem 409, Drug Assay Course Coordinator, P510, Pharmaceutical Care III: Pharmacy Practice Lecturer, P550, Career Development
2001	Course Coordinator, P510, Pharmaceutical Care III: Pharmacy Practice Lecturer, P550, Career Development
2000	Lecturer, P550, Career Development. Lecturer, P550, Negotiating the Deal Lecturer, Applications of Drug Assay in Clinical Research
1999	Lecturer, PHAD 696, Pharmacy Administration
1998-1999	Lecturer CLPH 572, Pathophysiology & Therapeutics II
1998	PP578 Advanced Therapeutics, Butler University College of Pharmacy
1992-1998	Lecturer CLPH 598 Pathophysiology & Advanced Therapeutics
1991-1997	Lecturer CLPH 597, Pathophysiology & Advanced Therapeutics
1988-1999	Lecturer and Section leader for PHPR 479, Patient Case Studies
1988-2000	Preceptor for CLPH 595, Advanced Clerkship for Pharm.D. students (Nephrology, Infectious Disease, General Surgery)
1992-1996	Lecturer for CLPH 567, Drug Information
1990-1996	Lecturer for CLPH 490C, Pharmacotherapeutics
1989-1996	Preceptor for CLPH 497, Clinical Clerkship (General Surgery)
1989-1990	Lecturer for IPPH 475, Pharmacokinetics
1989-1991	Lecturer for PHPR 597, Advanced Therapeutics
1989-1991	Discussion Leader for IPPH 575, Advanced Pharmacokinetics
1986-1988	Preceptor for PHR 366T for baccalaureate students
1987	Teaching Assistant for Drug Interactions PHR 171 for B.S. students

**Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

**POST-DOCTORAL TRAINING LEADERSHIP**

FELLOWSHIP IN NEPHROLOGY, PRIMARY PRECEPTOR FOR:

Deborah A. Pasko, Pharm.D., August 30, 2001-August 29, 2003  
Mariann Churchwell, Pharm.D., July 1, 2003- June 30, 2005  
Maricor Grio, M.D., July 1, 2005-June 30, 2007  
Jignesh Patel, Pharm.D., July 1, 2005-June 30, 2007  
Noha Salama, Ph.D., January 1, 2007- December 31, 2008  
Mary Vilay, Pharm.D., July 1, 2007-June 30, 2009  
Rachel F. Eyler, Pharm.D., July 1, 2009-June 30, 2011  
Bridget A. Scoville, Pharm.D., July 1, 2011-June 30, 2013  
Susan J. Lewis, Pharm.D., July 1, 2013-April 30, 2016  
Katherine N. Gharibian, PharmD, July 2014-June 2016  
Weerachai Chaijamorn, BS Pharm July 2015-June 2106  
Alexander R. Shaw, PharmD, July 2015-June 2017  
Soomin Jang, PharmD, April 2016-June 2018

SPECIALTY RESIDENCY IN ADULT MEDICINE PHARMACY PRACTICE PRIMARY PRECEPTOR FOR:

Patrick J. Heffernan, Pharm.D., July 1990-June 1991  
Dennis G. Brierton, Pharm.D., June 1991-June 1992  
Sheryl L. Follin Vondracek, Pharm.D., July 1994-June 1995  
Donald F. Brophy, Pharm.D., July 1995-June 1996

SPECIALTY RESIDENCY IN PEDIATRICS ADVISOR FOR:

William Prescott, Pharm.D., July 1, 2003-June 30, 2004

ACCP 2005 NEPHROLOGY MINI SABBATICAL PROGRAM, PRIMARY PRECEPTOR FOR:

Michael Bentley, Pharm.D., an Assistant Professor at the Virginia Commonwealth University School of Pharmacy and Clinical Pharmacist at Carilion Roanoke Memorial Hospital.

GENERAL CLINICAL RESIDENCY ADVISOR FOR:

Susan Gordon, Pharm.D., July 1, 2004-June 30, 2005



## **Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

### UNIVERSITY OF MICHIGAN COLLEGE OF PHARMACY PHARMD INVESTIGATION MENTOR:

Askhan Khabazian, 2001-2003	Elaine Ng, 2009-2011
Audrey Nakamura, 2001-2003	Ngoc Vu, 2009-2011
Candace Chu, 2003-2005	Sarah Thiel, 2009-2011
Fadi Frances, 2003-2005	Eric Lind, 2009-2011
Carla Freshwater, 2004-2006	Tiffany Yau, 2009-2011
Stephanie Kaucher, 2004-2006	John Andrew Lee, 2010-2013
Brian Church, 2005-2007	Farzad Daneshvar, 2010-2013
Eugene Kreys, 2005-2007	Anna Polso, 2010-2013
Kevin Fantich, 2006-2008	Abbie Leino, 2010-2013
Duong Nguyen, 2006-2008	John Nguyen, 2011-2014
Suprat Saely, 2006-2008	Azadeh Ali Moghaddam, 2011-2015
Anna Sutherland, 2006-2008	Jian P. Mei, 2011-2015
Alan Thomas, 2006-2008	Niloufar Daneshvar, 2015-2017
Karalea Rothenberg, 2007-2009	Jerry Li, 2016-2018
Ashley Higgins, 2009-2011	Kristina Kan 2017-2109
Peter Fleck, 2009-2011	Collin Morrison 2017-2109
Jeremy Ortwine, 2009-2011	Erika Kim 2017-2109
James Stevenson, 2009-2011	Andrew Dodson 2017-2109
James McKenzie, 2009-2011	
Tristan Murray, 2009-2011	
Chia Hsu, 2009-2011	

### UNIVERSITY OF MICHIGAN CLINICAL RESEARCH SUMMER PROGRAM MENTOR

Robert Schuck, 2007	Farzad Daneshvar, 2011
Katie Bentz, 2007	Jerry Li, 2015
Steven Hseuh, 2010	

### PURDUE UNIVERSITY GRADUATE PROGRAM:

Committee Member, M.S. student, Aroonrit Lucksiri, (School of Pharmacy) 1999-2000  
Committee Member, M.S. student, Niyati Shah, (School of Pharmacy) 1998-1999  
Committee Co-Chair, Ph.D. student, Meri Kay Scott (School of Pharmacy) 1993-7  
Committee Member, M.S. student, (School of Veterinary Medicine) Erle Douglas Murphey 1993-1995  
Committee Member, M.S. student, Marigel Vargas-Ruiz Constantiner, (School of Pharmacy) 1990-1992

## **Bruce A. Mueller, PharmD, FCCP, FASN, FNKF**

### **COLLEGE AND UNIVERSITY COMMITTEES**

2018-Present	2018 MICHR Distinguished Clinical and Translational Research Mentor Award Selection Committee
2011	Member, Enhancing the Admissions Interview Process Committee
2011-Present	School of Medicine Conflict of Interest Committee
2011- Present	SciVal Experts Governance Committee
2012-Present	University of Michigan Interprofessional Education Planning Committee
2004-Present	Member, Campus HIPAA Information Committee
2002-Present	Member, College of Pharmacy Policy Review Committee
2002-Present	Member, Department of Pharmacy Services Leadership Committee
2001-Present	Member, Department of Pharmacy Services' Continuing Education
2000-Present	Ex Officio Member, College of Pharmacy Executive Committee
2002-2003	Chair, College of Pharmacy Career Planning Committee
2001-2002	Member, College of Pharmacy Space Allocation and Utilization Committee
2000-2001	Chair, College of Pharmacy of Pharmacy Experiential Training Program
2000-2001	Member, College of Pharmacy Ad Hoc Review Committee
1999-2000	Member, School of Pharmacy Grievance Committee
1994-1998	Member, Pharm.D. Curriculum Development Committee
1997-1998	Pharmacy Practice Promotional and Tenure Guidelines Committee
1998	Review of the Department of Pharmacy Practice Head Committee
1997	Chair, Pharmacy Practice Clerkship Finance Committee
1995	Chair, Pharmacy Practice Head Search Committee Member, Organizational/Leadership Committee
1993	School of Pharmacy Undergraduate Curricula and Improvement of Instruction Committee
1993-1994	Member, Campus Grievance Committee, Purdue University
1992-1993	Alternate Member, Campus Grievance Committee, Purdue University.
1991-1992	School of Pharmacy Self-Study Committee (Physical Resources)
1990-1993	School of Pharmacy Pharm.D. Admissions and Standards Committee